Ned Pagliarulo

1238 ARTICLES BY Ned Pagliarulo

• Nov. 16, 2018 Pfizer tests Trump with plans to hike prices on 41 drugs
• Nov. 12, 2018 At SITC, clear wins for immunotherapy combos remain elusive
• Nov. 9, 2018 NASH drugs come into focus as field awaits late-stage data
• Nov. 8, 2018 AstraZeneca at 'inflection point' in turnaround, predicts CEO
• Nov. 7, 2018 5 election takeaways for pharma
• Nov. 6, 2018 Nektar lures Pfizer with promise of combo immunotherapy
• Nov. 2, 2018 Humira biosimilar discounting 'aggressive' as competition enters in Europe
• Nov. 2, 2018 Alkermes depression drug approval odds slim after negative FDA panel vote
• Nov. 1, 2018 Gilead's stock wobbles on HIV pricing concerns
• Nov. 1, 2018 Shingrix gives GSK a near-term boost
• Oct. 31, 2018 Novartis wins US nod for Humira biosimilar, but focus now on Europe
• Oct. 31, 2018 Come January, will pharma pricing pledges hold?
• Oct. 31, 2018 Merck's Keytruda secures broader lung cancer approval
• Oct. 29, 2018 Alkermes' depression drug set to test flexibility of FDA
• Oct. 29, 2018 Pfizer, Novartis partner in hunt to find drugs for NASH
• Oct. 28, 2018 Esperion clears final trial hurdle in bid to shake up cholesterol market
• Oct. 26, 2018 Amgen, Regeneron appear most at risk from Trump's latest pricing plan
• Oct. 25, 2018 Trump pitches new plan to bring US drug prices down
• Oct. 25, 2018 Keytruda growth fuels Merck investment
• Oct. 25, 2018 Biogen dips as BAN2401 data bring more questions than answers
• Oct. 24, 2018 Amgen cuts US Repatha price 60% amid market pressure
• Oct. 24, 2018 DTC's big issues: Trump, cancer drugs and the First Amendment
• Oct. 24, 2018 Reimbursement lags cancer drug approvals, but some European countries wait longer
• Oct. 24, 2018 Pfizer, Lilly avoid safety red flags in late-stage tanezumab trial
• Oct. 23, 2018 Advair copy approval 'imminent,' Mylan says, but investors jittery
• Oct. 22, 2018 Viagra no more: The changing face of drug ads on TV
• Oct. 22, 2018 ESMO 2018: What you missed over the weekend
• Oct. 20, 2018 Loxo's targeted therapy holds up to Roche challenge
• Oct. 20, 2018 Benefit of Roche's Tecentriq looks limited in breast cancer
• Oct. 19, 2018 Clovis aims at new market for cancer drug Rubraca
• Oct. 18, 2018 Novartis buys Endocyte for $2.1B in latest deal under CEO Narasimhan
• Oct. 17, 2018 Humira biosimilars launch in Europe, testing AbbVie
• Oct. 17, 2018 Biosimilars bite into Herceptin in Europe
• Oct. 16, 2018 5 questions on the Trump admin's bid to mandate prices in drug ads
• Oct. 15, 2018 Confronting pharma, Trump admin seeks price disclosure in drug ads
• Oct. 15, 2018 Under pressure, drugmakers give an inch on DTC drug ads
• Oct. 12, 2018 Opdivo misses survival goal in small-cell lung cancer study
• Oct. 11, 2018 Expansion gives Almac room to grow in North Carolina
• Oct. 11, 2018 US tightens scrutiny of foreign investment into biotech sector
• Oct. 10, 2018 Price increases on top drugs drove majority of recent growth, analysis finds
• Oct. 9, 2018 Trevena shares sink on FDA concerns ahead of key panel meeting
• Oct. 8, 2018 Loxo, Blueprint drive forward with RET-targeting cancer therapies
• Oct. 5, 2018 FDA clears rare disease therapy from Akcea, Ionis
• Oct. 5, 2018 Gilead reaches deal for Yescarta coverage in England
• Oct. 4, 2018 Sarepta gene therapy for DMD takes another step forward
• Oct. 3, 2018 Roche drug shows benefit in spinal muscular atrophy
• Oct. 3, 2018 In reversal, GSK to restart limited payments to doctors
• Oct. 2, 2018 Rare case of CAR-T resistance underscores manufacturing hurdles
• Oct. 1, 2018 10 biotechs set to shake up the industry's top ranks
• Oct. 1, 2018 Pfizer's Bourla to succeed Read as CEO
• Oct. 1, 2018 What you need to know about continuous manufacturing
• Sept. 29, 2018 Regeneron wins early approval for cancer immunotherapy
• Sept. 28, 2018 Alnylam puts its chips on speedy OK for rare disease drug
• Sept. 28, 2018 Cancer drug approval expands Pfizer's targeted therapy ambition
• Sept. 27, 2018 Lilly's migraine drug wins US approval, pressuring rivals Amgen, Teva
• Sept. 26, 2018 Merck CEO to stay on through 2019
• Sept. 25, 2018 AstraZeneca's Imfinzi shows its strength in Stage 3 lung cancer
• Sept. 25, 2018 Tecentriq sets the bar in small-cell lung cancer
• Sept. 24, 2018 Pharma's slow embrace of continuous manufacturing
• Sept. 24, 2018 Foundation Med advances liquid biopsy ambition with new test
• Sept. 20, 2018 Amicus expands into gene therapy with $100M deal
• Sept. 18, 2018 AbbVie accused of 'far-reaching' kickback scheme for Humira
• Sept. 18, 2018 Viking shares soar as NASH drug impresses
• Sept. 17, 2018 Will Ajovy lead Teva's turnaround?
• Sept. 14, 2018 Teva wins much-needed US approval of migraine drug
• Sept. 14, 2018 Allergan's Bonti buy part of plan to double medical aesthetics business
• Sept. 13, 2018 Sanofi looks to China in business restructure
• Sept. 13, 2018 Boehringer bets on oncolytic viruses in ViraTherapeutics deal
• Sept. 12, 2018 Gottlieb rebuffs pharma CEO who claimed price hikes were 'moral requirement'
• Sept. 12, 2018 Bristol-Myers' psoriasis drug proves itself in mid-stage study
• Sept. 11, 2018 Alcon to shift HQ to Switzerland after Novartis spinoff
• Sept. 10, 2018 Appeals court upholds CRISPR patent ruling in win for Broad Institute
• Sept. 10, 2018 FDA closes door to speedy OK for Amicus rare disease drug
• Sept. 7, 2018 GSK's pitch for Nucala in COPD turned down by FDA
• Sept. 7, 2018 Invokana gains heart labeling in Europe
• Sept. 6, 2018 GSK eliminates 650 jobs amid R&D revamp
• Sept. 6, 2018 Portola inches closer to large-scale Andexxa production
• Sept. 6, 2018 BioMarin pumps $43M into Ireland drug plant
• Sept. 6, 2018 FDA delays key Tecentriq decision by 3 months
• Sept. 5, 2018 Sangamo pitches gene therapy progress, yet investors stay skeptical
• Sept. 5, 2018 Chi-Med wins landmark cancer drug approval in China
• Sept. 4, 2018 Mannkind stays afloat with United licensing deal
• Aug. 29, 2018 Pfizer calls out pharma peers for 'scare tactics' on biosimilars
• Aug. 28, 2018 UK's NICE judges Yescarta too pricey, dealing blow to Gilead
• Aug. 27, 2018 FDA confronts its limits in push on drug pricing
• Aug. 27, 2018 Pfizer's tafamidis cuts risk of death in rare disease study
• Aug. 27, 2018 Esperion clears another milestone in bet on cholesterol pill
• Aug. 24, 2018 Lawmakers push to require price disclosure in DTC drug ads
• Aug. 23, 2018 Novartis' trial success revives PI3K potential in breast cancer
• Aug. 22, 2018 AbbVie brings Argenx drug onboard amid immuno-oncology push
• Aug. 21, 2018 HHS touts drug pricing 'wins,' but true tests still to come
• Aug. 20, 2018 Aimovig launch bolsters hopes for blockbuster sales
• Aug. 10, 2018 Amicus secures US approval for Fabry disease drug
• Aug. 10, 2018 In first, FDA approves RNA interference drug from Alnylam
• Aug. 9, 2018 CVS rejects pharma claim that rebates push up drug prices
• Aug. 8, 2018 AstraZeneca settles Texas suits claiming it mismarketed Crestor, Seroquel
• Aug. 8, 2018 Mylan to explore its options as North American business struggles
• Aug. 7, 2018 Express Scripts drops Mavyret from 2019 formulary in blow to AbbVie
• Aug. 7, 2018 Spark sheds $1B in value on hemophilia gene therapy data
• Aug. 6, 2018 Regeneron expands immuno-oncology push with Bluebird pact
• Aug. 3, 2018 Drugs make up more US health spending than thought, report suggests
• Aug. 2, 2018 AbbVie surprised investors with its hepatitis C success. Will it last?
• Aug. 2, 2018 Latest PRV sale further evidence of sliding value
• Aug. 1, 2018 Gilead spotlights Truvada ads as preventive use grows
• July 31, 2018 Pfizer CEO sees drug rebates 'going away' in US
• July 30, 2018 RedHill drug for Crohn's clears first Phase 3 hurdle
• July 27, 2018 AbbVie faith in Humira, future growth remains ironclad
• July 26, 2018 Sales of Roche new drugs are surging. Will that be enough?
• July 25, 2018 Positive Alzheimer's results from Biogen, Eisai spark 'cautious optimism'
• July 25, 2018 GSK secures US approval of new malaria drug
• July 24, 2018 Two-drug HIV regimen from GSK bolstered by Phase 3 data
• July 23, 2018 Seeking to adopt AI, drugmakers search for right mix of talent
• July 23, 2018 Sangamo to buy TxCell, cell therapy tech in $84M deal
• July 19, 2018 7 companies to watch during Q2 earnings
• July 19, 2018 Novartis hits CAR-T manufacturing snag as Kymriah sales disappoint
• July 19, 2018 Tecentriq misses another chance to catch Keytruda
• July 18, 2018 Drug lobby aims to shake up how medicines are paid for
• July 18, 2018 Novartis points to price hike pause, potentially dodging Pfizer fate
• July 17, 2018 Roche experimental flu drug clears second Phase 3
• July 16, 2018 Cassiopea prospects fill in as hair loss drug shows promise
• July 13, 2018 Novartis' contacts with Trump lawyer broader than company let on, US senators charge
• July 12, 2018 Novartis partners with French CDMO to bolster CAR-T supply
• July 12, 2018 Dermavant finds 'cornerstone' drug in GSK's pipeline
• July 11, 2018 Pfizer price hikes on pause after Trump pressure
• July 10, 2018 Aquinox cuts staff by 50% in wake of late-stage miss
• July 9, 2018 CTI cancer drug faces clouded future after study failure
• July 6, 2018 Biogen Alzheimer's drug shows unexpected signs of promise
• July 5, 2018 Prior authorization limits would be 'reasonable' for CGRP drugs, ICER says
• July 3, 2018 Catalent expands with $133M deal for Juniper
• July 2, 2018 Sanofi expands China presence with new R&D hub
• July 2, 2018 Tecentriq extends streak with win in breast cancer trial
• June 29, 2018 Galapagos posts 'underwhelming' cystic fibrosis results, boosting Vertex
• June 29, 2018 Biogen pays $700M to up stake in Samsung Bioepis
• June 28, 2018 Akebia, Keryx to merge, creating $1B kidney disease company
• June 27, 2018 Gottlieb calls out Perrigo for missed postmarket study deadline
• June 27, 2018 Global Blood bets sickle cell drug success will convince FDA
• June 26, 2018 FDA to pub surrogate endpoints used in cancer drug approvals
• June 26, 2018 Jardiance shows potential in type 1 diabetes, clearing Phase 3 tests
• June 25, 2018 Immunotherapy advances spur new look at cancer vaccines
• June 25, 2018 Roche aims for first-mover edge in small cell lung cancer
• June 21, 2018 Novo's case for oral semaglutide bolstered by Phase 3 trial wins
• June 20, 2018 Purdue Pharma lays off 350, cutting remainder of sales force
• June 20, 2018 Anika shares slump on Phase 3 miss
• June 19, 2018 Roche buys out Foundation Med in $2.4B bet on targeted cancer treatment
• June 18, 2018 Solid finds its footing as FDA lifts trial hold
• June 18, 2018 Valeant hit with CRL for key dermatology drug
• June 15, 2018 Bluebird's changes to LentiGlobin begin to pay off
• June 14, 2018 Recipharm to pay $60M for Sanofi manufacturing plant
• June 14, 2018 Sage licenses out depression drug in Asia, adding to cash warchest
• June 13, 2018 Biosimilars could still pack revenue-busting punch, analyst suggests
• June 13, 2018 FDA permits more expansive communication between drugmakers, payers
• June 12, 2018 Sun Pharma gets reprieve as FDA clears key Halol plant
• June 11, 2018 Allergan notches another CGRP success, but faces changing migraine market
• June 11, 2018 AbbVie, Roche win key US approval for blood cancer drug
• June 11, 2018 Sanofi partners with Translate Bio on mRNA vaccines
• June 7, 2018 Novartis won't face Swiss criminal probe over payments to Trump lawyer
• June 6, 2018 ASCO18: 3 unanswered questions from oncology's largest conference
• June 6, 2018 ASCO18: Who were the big winners and losers?
• June 5, 2018 ASCO18: Bristol-Myers fights for its place in first-line lung cancer
• June 3, 2018 ASCO18: Celgene makes its case as CAR-T rival in lymphoma
• June 3, 2018 ASCO18: Merck raises the bar in lung cancer with Keytruda data
• June 2, 2018 ASCO18: Bristol-Myers, Nektar forge ahead with Phase 3 tests for cancer combo
• June 1, 2018 ASCO18: Positive readout marks step forward for Bluebird's CAR-T
• May 31, 2018 Gilead's filgotinib clears mid-stage test in arthritis
• May 31, 2018 PhRMA criticizes ICER in latest skirmish over valuing drugs
• May 30, 2018 Allergan to sell off women's health, anti-infective businesses
• May 30, 2018 AstraZeneca won't submit lung drug for COPD after 2nd study miss
• May 29, 2018 Tecentriq trial wins boost Roche bid to compete with Merck
• May 25, 2018 AstraZeneca's Imfinzi delivers survival benefit in Stage 3 lung cancer
• May 24, 2018 Cancer drug spending climbs, with top winners earning lion's share
• May 22, 2018 Momentum grows for hemophilia gene therapies
• May 21, 2018 Regeneron's Aris Baras on probing the genome to find drugs for NASH
• May 21, 2018 Pharma turn to NASH unlikely to mirror meteoric rise of hep C
• May 21, 2018 FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq
• May 18, 2018 Celgene, J&J top complaint list to FDA for blocking generics
• May 17, 2018 5 takeaways from the first look at cancer's biggest conference
• May 16, 2018 To shame drugmakers, CMS publicizes price hikes
• May 16, 2018 Top Novartis lawyer to exit over deal with Trump insider
• May 15, 2018 Gilead finds new home in Europe for CAR-T manufacturing
• May 14, 2018 Bluebird widens hunt for TCR therapies in revised Medigene deal
• May 11, 2018 AstraZeneca lung drug comes up short in COPD
• May 10, 2018 Tecentriq stumbles in Phase 3 colon cancer study
• May 9, 2018 Walmart to limit opioid prescriptions to 7-day supply
• May 9, 2018 Novartis paid $1.2M to firm linked to Trump attorney
• May 8, 2018 Takeda secures Shire takeover with $62B deal
• May 7, 2018 J&J's ketamine-based antidepressant sees mixed results in Phase 3
• May 5, 2018 Merck bets Moderna's mRNA tech can unlock KRAS puzzle
• May 4, 2018 FDA approves Andexxa in major boost to Portola
• May 3, 2018 Fremanezumab approval by mid-June unlikely, Teva says
• May 2, 2018 Regeneron, Sanofi drop PCSK9 price in deal with Express Scripts
• May 2, 2018 IDO drug development scaled back in wake of Incyte trial miss
• May 1, 2018 Merck, riding clinical success, eyes cancer immunotherapy lead
• May 1, 2018 Q1 earnings preview: Novo, Celgene still to come
• April 30, 2018 Saunders: All options remain on the table for Allergan
• April 26, 2018 Opdivo sales rise again, but analysts question what's next
• April 26, 2018 Ocrevus fuels fast start to year for Roche
• April 25, 2018 Biogen to increase stake in biosimilar developer Samsung Bioepis
• April 25, 2018 GSK new drug success eclipsed by currency, Advair slump
• April 24, 2018 Immunotherapies, biosimilars to dominate next week of earnings
• April 24, 2018 Setback for AstraZeneca cancer combo raises MYSTIC stakes
• April 24, 2018 Lilly raises sales forecasts as diabetes drugs outperform
• April 23, 2018 As India, China drug industries mature, FDA scrutiny an overhang
• April 23, 2018 Top challenges facing drug supply chains
• April 23, 2018 Pfizer's Herceptin copy hits FDA roadblock
• April 20, 2018 Biogen, facing questions, turns again to Ionis in $1B research deal
• April 19, 2018 Astellas sells Agensys facilities to Gilead
• April 19, 2018 Cosentyx jitters weigh on Novartis
• April 18, 2018 Pushing 'value,' Harvard Pilgrim tests outcomes deals
• April 18, 2018 DEA seeks to more strictly manage opioid manufacturing
• April 17, 2018 Sanofi nears deal to sell EU generics unit for $2.4B
• April 16, 2018 Two years after cancer setback, Bristol-Myers' new biomarker bet pays off
• April 16, 2018 I/O combos inch forward in pharma's lung cancer quest
• April 13, 2018 Q1 kicks off with J&J, Novartis, Glaxo results
• April 12, 2018 Lonza makes gene therapy ambitions clear with Texas plant
• April 12, 2018 GSK offloads gene therapy drugs to UK's Orchard
• April 11, 2018 CVS hands pharmacists tool to compare drug prices
• April 11, 2018 Pfizer's Inlyta misses mark in Phase 3 kidney cancer study
• April 9, 2018 With study success, AbbVie's arthritis hopeful looks to be a safer bet
• April 9, 2018 Novartis buys AveXis for $8.7B, broadening gene therapy bet
• April 6, 2018 AbbVie staves off another biosimilar challenge to Humira
• April 6, 2018 Incyte cancer study fails, setting back drug combo hopes
• April 5, 2018 Corning to build NC facility in pharma packaging expansion
• April 5, 2018 Boehringer joins checkpoint inhibitor race with OSE deal
• April 4, 2018 Alnylam taps Agilent for commercial API supply
• April 4, 2018 Amgen's money-back offer on Repatha isn't all that meaningful, researchers find
• April 4, 2018 Proposed China tariffs target dozens of medical products
• April 3, 2018 Rigel's fostamatinib falls short in Phase 2
• April 2, 2018 Pfizer surprises ATTR rivals with tafamidis success
• March 29, 2018 Eisai partners with Nichi-Iko in generics pact
• March 29, 2018 Indivior inks deal for preclinical addiction treatment candidate
• March 28, 2018 PhRMA goes after drug 'middlemen' in new ad attack
• March 28, 2018 Roche reports deaths of patients taking Hemlibra
• March 27, 2018 GSK buys Novartis stake in consumer business for $13B
• March 26, 2018 Lilly's bet on pain stands out amid bare pharma pipeline
• March 26, 2018 Roche's momentum grows as Tecentriq combo delivers survival benefit
• March 23, 2018 GSK drops bid to acquire Pfizer's consumer business
• March 22, 2018 Novartis readies MS drug for speedy US filing
• March 22, 2018 FDA warns Indian drugmaker over open-air API production
• March 22, 2018 Regeneron, Alnylam partner to turn discovery into new drugs for NASH
• March 21, 2018 Seattle Genetics secures key label expansion for Adcetris
• March 20, 2018 Tecentriq combo success boosts Roche in lung cancer
• March 19, 2018 Heron's non-opioid pain drug succeeds in Phase 3, lifting shares
• March 16, 2018 Ionis taps majority-owned Akcea to launch inotersen
• March 15, 2018 Novartis splits operations unit as part of leadership reshuffle
• March 15, 2018 SEC charges against Theranos, Holmes dispel last shreds of unicorn myth
• March 14, 2018 Federal panel calls for 'urgent action' on cancer drug prices
• March 14, 2018 Incyte study could bring lessons for cancer immunotherapy
• March 13, 2018 Teva hands back rights to preclinical CGRP blocker
• March 12, 2018 AstraZeneca pushes back readout of key lung cancer study
• March 10, 2018 Regeneron-Sanofi cholesterol drug cuts heart risk in major study
• March 9, 2018 Despite crowded I/O field, pharma, VCs still eager to invest
• March 8, 2018 FDA recognizes GMP inspections by 4 more EU states
• March 8, 2018 Merck partners with Eisai in sweeping bet on Keytruda combo
• March 6, 2018 UnitedHealthcare to use rebates to lower drug costs for patients
• March 5, 2018 Santhera shares slide as Raxone fails in MS study
• March 5, 2018 Dermira acne drug misses the mark, surprising investors
• March 2, 2018 Roche, Ionis showcase potential of Huntington's disease drug
• March 1, 2018 Regeneron links rise in Eylea safety reports to syringes
• March 1, 2018 Mylan partners with Revance to develop a Botox biosimilar
• Feb. 28, 2018 Benzo overprescribing risk may be overlooked amid opioid crisis
• Feb. 28, 2018 AstraZeneca spins out new biotech, shedding autoimmune drugs
• Feb. 27, 2018 Lilly wins broader Verzenio approval, drawing even with rivals
• Feb. 26, 2018 Messy Phase 2 data for Arca's heart drug leave investors unimpressed
• Feb. 26, 2018 Cancer and the microbiome: What's old is new again
• Feb. 26, 2018 Patent board ruling undermines Allergan effort to defend Restasis patents
• Feb. 23, 2018 Bellicum outlines path to restart US studies of cell therapy
• Feb. 20, 2018 CAR-T growing up with big pharma's big bet
• Feb. 15, 2018 Charles River boosts CRO chops with $800M deal for MPI
• Feb. 15, 2018 Biogen shares fall after unexpected 'variability' in Alzheimer's studies
• Feb. 14, 2018 Bristol-Myers bets $1.85B on combo potential of Nektar cancer drug
• Feb. 13, 2018 Teva's Copaxone sales hit hastened with OK of Novartis copy
• Feb. 12, 2018 Maker of Oxycontin to halt opioid promotion to doctors
• Feb. 9, 2018 Boehringer ends Alzheimer's research for PDE9 blocker
• Feb. 8, 2018 FDA warning letter details violations at Celltrion plant
• Feb. 8, 2018 Citing lower tax rate, Amgen plans new biomanufacturing plant
• Feb. 8, 2018 FDA knocks back Novartis' Advair copy
• Feb. 7, 2018 Express Scripts: Plan drug spending rose at slowest rate in 24 years
• Feb. 7, 2018 Mixed results muddy Sanofi's plans for 2018 growth
• Feb. 6, 2018 Gilead forecasts steep slide in 2018 hepatitis C revenues
• Feb. 5, 2018 Strong data lift profile of J&J's cancer drug apalutamide
• Feb. 5, 2018 Biopharma in charts: Key takeaways from Q4 earnings
• Feb. 2, 2018 Keytruda boosts Merck, yet 2018 will be crucial year
• Feb. 1, 2018 Celltrion biosimilars plant hit with FDA warning letter
• Feb. 1, 2018 Pharma tees up US capital spending, yet details remain vague
• Feb. 1, 2018 FDA adds black box warning to Intercept's Ocaliva
• Jan. 31, 2018 Aegerion sentenced for mismarketing of cholesterol drug
• Jan. 31, 2018 Boosted by tax reform, Lilly looking for ways to spend $9B
• Jan. 29, 2018 How Bristol-Myers and Pfizer are using real-world data to unseat warfarin
• Jan. 29, 2018 5 Drivers spurring use of real-world evidence
• Jan. 29, 2018 Aradigm stung by FDA rejection of inhaled antibiotic
• Jan. 26, 2018 AbbVie shares boom on rosy outlook
• Jan. 25, 2018 Chinese drugmakers tap GE tech, seeing biologic boom ahead
• Jan. 25, 2018 Spark deals Novartis ex-US rights to gene therapy for $105M
• Jan. 24, 2018 US in 'desperate need' of biosimilars: Novartis' Narasimhan
• Jan. 24, 2018 Novartis pulls Arzerra outside US markets amid rising CLL competition
• Jan. 24, 2018 Novartis predicts growth pick-up on back of Cosentyx, Entresto
• Jan. 23, 2018 Astellas, Vical's CMV vaccine comes up short in Phase 3
• Jan. 22, 2018 Celgene buys Juno for $9B, deepening bet on CAR-T
• Jan. 19, 2018 FDA to speed public notification of product recalls
• Jan. 18, 2018 Ipca Labs buys North Carolina manufacturer for $9.7M
• Jan. 18, 2018 With eye to Brexit, Almac to invest $42M in Ireland site
• Jan. 18, 2018 Patent setback could sting J&J prostate cancer franchise
• Jan. 17, 2018 Exelixis details Phase 3 cabozantinib results
• Jan. 16, 2018 Price for Spark gene therapy too high, ICER says
• Jan. 12, 2018 BioPharma Dive's 3 predictions for 2018 and beyond
• Jan. 11, 2018 Closing JPM18: Winners and losers, brighter days for neuroscience
• Jan. 10, 2018 JPM18 Day 3: Valeant and Acorda make plans, promises of M&A
• Jan. 10, 2018 Price competition to hit oncology next: BioPharma Dive's 2018 predictions
• Jan. 9, 2018 JPM18: Bluebird set to file 3 drugs for approval by 2019
• Jan. 9, 2018 JPM18 Day 2: Roche on gene therapy, Aimmune nears key readout and outpatient CAR-T
• Jan. 8, 2018 JPM18 Day 1: Celgene bullish, Alnylam tempers hopes, Axovant shocks
• Jan. 7, 2018 Celgene aims to quell growth worries with $7B Impact deal
• Jan. 7, 2018 Pfizer pulls back from neuroscience, ending research
• Jan. 5, 2018 FDA rejects Allergan's latest bid to block Restasis copies
• Jan. 4, 2018 FDA aims to strengthen oversight of compounded drug manufacturing
• Jan. 4, 2018 MacroGenics finds new pharma partner in Roche
• Jan. 3, 2018 Drug approvals surged in 2017. What does that mean for pharma?
• Jan. 3, 2018 Allergan to cut 1,000 jobs as generic competition threatens
• Jan. 3, 2018 Pfizer teams up with Sangamo to develop ALS gene therapy
• Jan. 2, 2018 J&J builds case for ketamine-based depression drug
• Dec. 26, 2017 Mallinckrodt builds pipeline through $1.2B Sucampo deal
• Dec. 22, 2017 J&J enters CAR-T field with $350M Legend deal
• Dec. 22, 2017 Biopharma trends to watch in 2018
• Dec. 21, 2017 Kymriah, Yescarta could be cost-effective, ICER finds
• Dec. 21, 2017 Juno inks CAR-T supply deal with Thermo Fisher
• Dec. 20, 2017 Galera scores trial win for cancer side effect treatment
• Dec. 19, 2017 FDA approves Spark blindness drug in gene therapy first
• Dec. 19, 2017 Aerie eyes glaucoma market after early FDA win
• Dec. 18, 2017 Novartis buys regulatory fast pass for $130M
• Dec. 15, 2017 Trial miss sets back Merck's Keytruda plans in stomach cancer
• Dec. 14, 2017 EMA signs off on Samsung BioLogics manufacturing plant
• Dec. 14, 2017 FDA warns Korean OTC manufacturer for GMP violations
• Dec. 14, 2017 Regeneron's play for a stake in the I/O market boosted by study success
• Dec. 13, 2017 ASH 2017: What you missed
• Dec. 12, 2017 ASH17: J&J's Darzalex delivers combo win
• Dec. 11, 2017 ASH17: Spark gene therapy falls behind BioMarin in hemophilia
• Dec. 10, 2017 Shire CEO: Hemophilia will remain a core business
• Dec. 10, 2017 ASH17: Benefit of Gilead's CAR-T remains durable over longer term
• Dec. 10, 2017 ASH17: Seattle Genetics sees market opportunity in cancer combo success
• Dec. 9, 2017 ASH17: bluebird bio makes strides in CAR-T, gene therapy
• Dec. 9, 2017 ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia
• Dec. 7, 2017 Gilead deepens CAR-T push with deal for Cell Design
• Dec. 7, 2017 Chasing leaders, Juno rides CAR-T momentum into ASH
• Dec. 7, 2017 Wuxi preps for biologics manufacturing surge in China
• Dec. 7, 2017 Roche's Tecentriq combo cuts risk of lung cancer progression
• Dec. 6, 2017 Biogen inks outcomes-based contract for MS meds
• Dec. 6, 2017 FDA cautiously lifts holds on combo studies of checkpoint inhibitors
• Dec. 4, 2017 Updated: Sanofi discontinues C. diff candidate in blow to vaccine unit
• Dec. 4, 2017 7 Biopharmas to watch at ASH 2017
• Dec. 4, 2017 Mylan wins first US approval of Herceptin biosimilar
• Dec. 4, 2017 Most Impressive Drug Launch: Roche's Ocrevus
• Dec. 4, 2017 Deal of the Year: Gilead Buys Kite Pharma
• Dec. 4, 2017 The BioPharma Dive Awards for 2017
• Dec. 1, 2017 Bayer unblinds cancer drug study early to investigate patient deaths
• Nov. 30, 2017 Corning adds 185 jobs to support pharma packaging production
• Nov. 30, 2017 Sanofi to propose limits on use of dengue vaccine after safety signal
• Nov. 29, 2017 FDA knocks generic maker for misbranding sleep aid
• Nov. 28, 2017 Biopharma in charts: New drugs and the search for growth
• Nov. 28, 2017 Pfizer, Merck KGaA's Bavencio falls short in gastric cancer study
• Nov. 27, 2017 AstraZeneca launches JV, furthering play for China market
• Nov. 27, 2017 Teva restructures to stabilize struggling business
• Nov. 22, 2017 J&J eyes broader market for blood cancer med Darzalex
• Nov. 22, 2017 GSK boosted by US approval of two-drug HIV pill
• Nov. 21, 2017 Cytokinetics to discontinue ALS drug after Phase 3 miss
• Nov. 20, 2017 Roche lung cancer results boost Tecentriq versus I/O rivals
• Nov. 17, 2017 Proposed Medicare policy could shift drug rebates to consumers
• Nov. 16, 2017 Recipharm to shutter two plants, cutting 225 jobs
• Nov. 16, 2017 Avista doubles API manufacturing capacity at CO facility
• Nov. 16, 2017 Quotient Sciences buys UK CDMO in third acquisition of year
• Nov. 16, 2017 Janssen picks up second GI drug from Ionis
• Nov. 15, 2017 Novartis sets Cosentyx hopes higher
• Nov. 15, 2017 AstraZeneca wins US approval for asthma biologic
• Nov. 14, 2017 Loxo parlays cancer drug success into $1.5B deal with Bayer
• Nov. 13, 2017 Novartis turns to startup to boost gene editing efforts
• Nov. 13, 2017 Zymeworks adds 6th pharma partner with J&J deal
• Nov. 10, 2017 Juno analysis of shuttered study offers clues for CAR-T
• Nov. 9, 2017 Sage shares boom on success of postpartum depression drug
• Nov. 8, 2017 'Hard' Brexit risks disrupting supply of thousands of drugs
• Nov. 8, 2017 Roche to shift packaging operations, trimming 235 jobs
• Nov. 8, 2017 Spark gene therapy for blindness could come at steep cost
• Nov. 8, 2017 Regeneron boosted by Eylea strength
• Nov. 7, 2017 FDA lifts clinical hold on Cellectis CAR-T
• Nov. 6, 2017 FDA agrees to review TherapeuticsMD drug, dropping safety demands
• Nov. 3, 2017 One-two punch hits Teva, sparking worries about debt
• Nov. 2, 2017 FDA to recognize GMP inspections by 8 EU drug regulators
• Nov. 2, 2017 Diabetes drags on Sanofi, even as Dupixent shines
• Nov. 1, 2017 ICER looks to expand watchdog role with new funding
• Nov. 1, 2017 AstraZeneca secures US approval for 'cornerstone' cancer drug
• Nov. 1, 2017 Bluebird marks progress on Lentiglobin gene therapy
• Oct. 31, 2017 AstraZeneca looks to build edge in early-stage lung cancer
• Oct. 30, 2017 Pharma's betting big on China, but R&D boom still to come
• Oct. 30, 2017 Novartis bolsters oncology with $3.9B Advanced Accelerator buy
• Oct. 27, 2017 Merck sales slip, even as Keytruda gains ground
• Oct. 26, 2017 What to expect from the rest of pharma's earnings
• Oct. 26, 2017 Gilead warns hep C sales could fall further
• Oct. 26, 2017 Drug production in Puerto Rico still disrupted, FDA says
• Oct. 26, 2017 Lilly to spend $72M on upgrading insulin production
• Oct. 26, 2017 Vertex grows CF franchise as combos move forward
• Oct. 25, 2017 With Advair copies looming, GSK keeps focus on new drugs
• Oct. 24, 2017 Eyes on Alcon as Novartis notches modest growth
• Oct. 23, 2017 Vaccine approval buoys GSK new drug push
• Oct. 20, 2017 What's next for biopharma Q3 earnings
• Oct. 19, 2017 Gritstone taps Arbutus' LNP tech for RNA-based therapies
• Oct. 19, 2017 J&J says Puerto Rico plants returning to full operations
• Oct. 18, 2017 Gilead wins US approval for CAR-T cancer therapy
• Oct. 18, 2017 Despite increased spending, orphan drugs still small piece of US medicines market
• Oct. 18, 2017 In Congressional spotlight, drug industry groups blame each other
• Oct. 17, 2017 Amneal, Impax combine amid generics crunch
• Oct. 16, 2017 Federal judge invalidates Restasis patents in blow to Allergan
• Oct. 16, 2017 Exelixis continues to gain momentum with positive data
• Oct. 13, 2017 What Q3 earnings will look like for 5 pharma giants
• Oct. 12, 2017 Spark's gene therapy for blindness takes major step toward approval
• Oct. 12, 2017 Pfizer sells off Colorado facility to CordenPharma
• Oct. 12, 2017 Sanofi commits €170M to expand flu vaccines production
• Oct. 11, 2017 Long rundowns of side effects can make drugs seem less risky, study finds
• Oct. 11, 2017 Lupin expands US presence with $150M Symbiomix deal
• Oct. 10, 2017 Lilly's plans for abemaciclib dented by lung trial miss
• Oct. 9, 2017 Flexion secures US approval for osteoarthritis drug
• Oct. 3, 2017 Strong data for Pompe therapy boosts Amicus
• Oct. 3, 2017 Rigel blood drug hits mark in mid-stage study
• Oct. 2, 2017 Express Scripts: Specialty meds driving up US drug spend
• Oct. 2, 2017 Arbutus boosted by $116M investment from Roivant
• Sept. 29, 2017 Zogenix looks to filing after epilepsy trial success
• Sept. 29, 2017 A drug 15 years in the making: Alnylam's quest to prove RNAi
• Sept. 28, 2017 Abeona taps Brammer Bio for gene therapy manufacturing support
• Sept. 27, 2017 AbbVie to keep limits on price hikes next year, denying backtrack
• Sept. 26, 2017 Axovant's closely watched Alzheimer's drug fails late-stage trial
• Sept. 25, 2017 Without power, Puerto Rico's drug manufacturing left battered by Maria
• Sept. 25, 2017 Premium price for Novartis' CAR-T sparks pushback from top PBM
• Sept. 22, 2017 Versartis crashes after Phase 3 miss
• Sept. 21, 2017 Brammer Bio doubles manufacturing capacity at Florida site
• Sept. 21, 2017 Provention builds pipeline with Janssen licensing deal
• Sept. 20, 2017 Alnylam soars on trial win for RNAi drug
• Sept. 19, 2017 Bayer ends sales of Essure implant outside of US
• Sept. 19, 2017 GSK's respiratory business boosted by lung drug approval
• Sept. 18, 2017 AbbVie, Roche to seek broader market for leukemia drug after trial success
• Sept. 18, 2017 Smaller sales forces get the job done in rare disease
• Sept. 18, 2017 Nabriva shares leap higher on antibiotic trial success
• Sept. 15, 2017 Samsung Bioepis first to secure EMA backing for Herceptin biosimilar
• Sept. 14, 2017 Amgen, Allergan win first approval of cancer biosimilar in US
• Sept. 14, 2017 FDA calls for industry input on continuous manufacturing guidelines
• Sept. 14, 2017 Pfizer, Astellas eye wider market for prostate cancer drug
• Sept. 13, 2017 Amicus drops wound drug after trial miss
• Sept. 12, 2017 ICER analysis latest salvo in debate over Repatha price
• Sept. 12, 2017 Sage stock sinks after epilepsy drug fails to beat placebo
• Sept. 11, 2017 Blockbuster hopeful Dupixent succeeds in asthma study
• Sept. 11, 2017 ESMO: New momentum for AstraZeneca as lung cancer studies impress
• Sept. 9, 2017 ESMO: Lilly breast cancer drug keeps pace with Pfizer, Novartis rivals
• Sept. 8, 2017 ESMO: Foundation biomarker test could help boost immunotherapy
• Sept. 7, 2017 Opdivo combo shows early survival benefit in kidney cancer
• Sept. 7, 2017 Cell therapy emergence opens up new markets for shippers, logistic companies
• Sept. 7, 2017 AstraZeneca sees first-in-class potential for asthma biologic
• Sept. 6, 2017 FDA warns drugmaker over misleading marketing of opioid
• Sept. 6, 2017 Verastem bet on blood cancer drug pays off with trial success
• Sept. 1, 2017 Industry Pulse: 10 charts on M&A, I/O and biosimilar threats
• Sept. 1, 2017 Janssen drops MacroGenics cancer candidate over safety concerns
• Aug. 31, 2017 Landmark approval won, Novartis' next test is scaling CAR-T manufacturing
• Aug. 31, 2017 Incyte, Merck build case for skin cancer combo
• Aug. 30, 2017 In historic first, FDA approves Novartis CAR-T therapy
• Aug. 30, 2017 Lilly speeds up timeline for refiling of baricitinib
• Aug. 29, 2017 AstraZeneca strikes $400M deal with Takeda for Parkinson's drug
• Aug. 28, 2017 Bristol-Myers, Pfizer continue to build case for Eliquis
• Aug. 27, 2017 Novartis rare disease drug opens up new way to treat heart disease
• Aug. 25, 2017 Regenxbio picks up Dimension in $86M stock deal
• Aug. 24, 2017 Samsung Bioepis locks down EU approval for Humira biosimilar
• Aug. 24, 2017 FDA warns compounding pharmacy of wood contamination
• Aug. 24, 2017 Roche lines up February decision date for hemophilia prospect
• Aug. 23, 2017 Pfizer secures patent in India for pneumonia vaccine
• Aug. 23, 2017 In cost debate, Amgen stands by Repatha's value
• Aug. 22, 2017 PCSK9 inhibitors still too pricey, study finds
• Aug. 21, 2017 Ironwood wins FDA approval for combo gout drug
• Aug. 21, 2017 Samsung Bioepis partners with Takeda to break into novel biologics
• Aug. 18, 2017 Expanded label boosts AstraZeneca and Merck's Lynparza
• Aug. 17, 2017 House Democrats to probe 'skyrocketing' prices for MS meds
• Aug. 17, 2017 Valeant says FDA to reclassify troubled Tampa plant
• Aug. 17, 2017 CEOs break with Trump amid disintegration of business councils
• Aug. 16, 2017 Bristol-Myers' Opdivo comes up short in kidney cancer study
• Aug. 15, 2017 Amid CEO exits, J&J chief to stay on Trump manufacturing council
• Aug. 15, 2017 Mundipharma picks up chemo prodrug in $250M deal
• Aug. 14, 2017 As federal efforts slow, states take up drug pricing pushback
• Aug. 14, 2017 Merck CEO resigns from Trump's manufacturing council
• Aug. 10, 2017 PharmaTech liquid drugs possibly contaminated, FDA says
• Aug. 10, 2017 Manufacturing issues threaten delay for Aerie eye drug
• Aug. 10, 2017 Alnylam review turns up no clear answers on revusiran deaths
• Aug. 9, 2017 Mylan cuts sales forecast as pricing pressure grows
• Aug. 8, 2017 Roche sells off dermatitis drug to Dermira
• Aug. 7, 2017 Lilly's turn to pain gathers momentum
• Aug. 4, 2017 Payer coverage boosts Radius' Tymlos
• Aug. 3, 2017 J&J set back by negative panel vote for sirukumab
• Aug. 2, 2017 Cytokinetics inches forward with heart failure program
• Aug. 1, 2017 Vertex wins new Kalydeco approval, ups sales forecast
• July 31, 2017 Express Scripts shuts out 64 branded drugs from 2018 formulary
• July 28, 2017 Unfazed by competition, Allergan sees room at CGRP table
• July 28, 2017 AbbVie confident in strategy as Humira mints money
• July 27, 2017 GSK looks to exit rare diseases
• July 27, 2017 Novartis taps Cryoport for CAR-T logistics support
• July 27, 2017 Corning invests $500M to build better glass packaging for pharma
• July 27, 2017 MYSTIC flop a major blow to AstraZeneca's I/O hopes
• July 26, 2017 Merck undercuts Pfizer on Remicade biosimilar price
• July 26, 2017 GSK overhauls R&D, axes 30 programs to regain edge
• July 25, 2017 Lilly maps out new approach to cancer R&D
• July 24, 2017 Nektar secures $400M deal with Lilly for Phase 1 drug
• July 17, 2017 5 trends shaping Alzheimer's drug development
• July 13, 2017 Amid supply shortage, FDA clears import of in-demand drug
• July 13, 2017 Lilly extends patent runway for Cialis
• July 12, 2017 FDA panel unanimously backs approval of Novartis CAR-T
• July 11, 2017 FDA changes tune on Amicus Fabry disease drug
• July 10, 2017 Safety issues for Novartis CAR-T therapy main focus of FDA
• July 7, 2017 Generic drug association sues to stop state price-gouging law
• July 6, 2017 Novo Nordisk recalls six batches of insulin cartridge holders
• July 6, 2017 3 Keytruda studies put on clinical hold after deaths
• July 5, 2017 Industry paid $8.2B to docs, hospitals last year
• July 5, 2017 Daiichi Sankyo pulls plug on Coherus biosimilar
• June 30, 2017 A head above the rest? Drugmakers face off in migraine market
• June 29, 2017 Patheon maps out $45M investment in services network
• June 29, 2017 Chemicals giant BASF builds out ibuprofen API production
• June 29, 2017 Exelixis clears debt, turning eye to future growth
• June 28, 2017 SEC charges ex-Ariad employees with insider trading
• June 27, 2017 Alder scores CGRP win but investors not impressed
• June 26, 2017 Alnylam lines up Phase 3 for another RNAi drug
• June 26, 2017 Seattle Genetics' Adcetris succeeds in study but shares slide
• June 23, 2017 CHMP decisions: Novartis locks up backing for Kisqali
• June 23, 2017 Mylan board weathers shareholder challenge
• June 23, 2017 FDA surprises with rejection of Pfizer's Epogen biosimilar
• June 22, 2017 Takeda set to open new German manufacturing facilities
• June 21, 2017 FDA targets regulatory 'gaming' to boost generic competition
• June 21, 2017 Report: Biopharma dealmaking set to level off
• June 20, 2017 FDA approves new antibiotic for skin infections
• June 19, 2017 Clovis soars on strong results for PARP inhibitor
• June 15, 2017 BioMarin secures FDA approval for Ireland production facility
• June 15, 2017 Sanofi continues biologics push, building on recent approvals
• June 15, 2017 Novartis, Verily back new $300M fund for European biotechs
• June 14, 2017 Rebates not to blame for rising drug costs, says PBM trade group
• June 14, 2017 How Merck hopes to win in I/O combos: Q&A with Roy Baynes
• June 13, 2017 Supreme Court ruling gives biosimilar makers a boost
• June 12, 2017 Gene therapy by the numbers
• June 12, 2017 ADA: Merck, Pfizer notch success, but late with SGLT-2 data
• June 7, 2017 Novartis' CAR-T stacks up to Kite in lymphoma
• June 6, 2017 ASCO17: CAR-Ts steal the show
• June 5, 2017 ASCO17: Juno marks progress with second-gen CAR-T
• June 5, 2017 ASCO 2017: What you missed
• June 5, 2017 ASCO17: Roche's Perjeta cuts risk in Aphinity, but is it enough?
• June 5, 2017 ASCO17: Roche's Alecensa bests Xalkori in lung study
• June 4, 2017 ASCO17: AstraZeneca's Lynparza stays step ahead of PARP rivals
• June 3, 2017 ASCO17: Incyte pads its IDO numbers
• June 3, 2017 ASCO17: Loxo shows promise of biomarker approach to cancer
• June 1, 2017 FDA cites Braun Medical for repeat GMP violations
• June 1, 2017 Chiltern acquires Japanese CRO in Asia expansion bid
• June 1, 2017 US may have overpaid $1.3B for Mylan's EpiPen, HHS watchdog says
• May 31, 2017 Drug rebates may shift costs to Medicare, study finds
• May 31, 2017 AstraZeneca taps outcomes deals to boost CV, diabetes meds
• May 30, 2017 Gilead tees up filing for HIV triple combo after Phase 3 wins
• May 30, 2017 Industry Pulse: R&D spending in charts
• May 26, 2017 Industry Pulse: Aging blockbusters tax bottom lines
• May 25, 2017 Problems at Sun Pharma plant trip up drug approval
• May 25, 2017 J&J settles OTC manufacturing issue for $33M
• May 25, 2017 Aerie shares rise on trial success for eye drug
• May 24, 2017 Under new CEO, Alexion continues overhaul of leadership
• May 23, 2017 Trial success buoys AstraZeneca's hopes for asthma biologic
• May 23, 2017 Overcoming delay, Sanofi, Regeneron win US approval for RA drug
• May 22, 2017 Celgene MS drug succeeds in second Phase 3 study
• May 22, 2017 Safety signal derails expected approval of Amgen bone drug
• May 18, 2017 Thermo Fisher to buy Patheon in $7.2B deal, accelerating CDMO consolidation
• May 18, 2017 7 Areas to watch from the ASCO abstracts
• May 17, 2017 FDA warns of higher amputation risk for J&J's Invokana
• May 17, 2017 Coherus wins Humira patent ruling, chipping away at AbbVie's defenses
• May 16, 2017 Taking office, Gottlieb keeps drug pricing front and center
• May 15, 2017 EU investigating generic drugmaker over cancer drug price hikes
• May 15, 2017 Can value-based deals work if patients don't take the drug?
• May 12, 2017 AstraZeneca rises after positive lung cancer results for key drug
• May 11, 2017 Indian drugmaker stages worker strike to avoid FDA inspection
• May 11, 2017 Second Advair copy rejected, giving GSK short-term respite
• May 11, 2017 Merck bolsters I/O edge with Keytruda combo approval
• May 10, 2017 Senate confirms Scott Gottlieb as FDA chief
• May 10, 2017 PhRMA ousts 22 drugmakers from ranks in membership change
• May 9, 2017 Valeant pitches a turnaround but new roadblocks complicate story
• May 8, 2017 Kite discloses patient death in CAR-T trial, sparking safety worries
• May 4, 2017 Pfizer making progress on Hospira manufacturing issues, execs say
• May 4, 2017 BIO accuses insurer report of shifting blame on drug prices
• May 3, 2017 Weak Xtandi sales spur questions on Pfizer's $14B Medivation takeover
• May 3, 2017 Pieris teams up with AstraZeneca on respiratory drug development
• May 2, 2017 Amgen inks first money-back guarantee for Repatha
• May 2, 2017 Merck sees Keytruda gains, offsetting generic hits to sales
• May 1, 2017 Q1 Earnings Preview: Gilead, Merck, Pfizer, Allergan
• April 30, 2017 Radius targets quick ramp up for newly approved osteoporosis drug
• April 28, 2017 Diabetes decline hangs over Sanofi's growth in specialty care, immunology
• April 27, 2017 Sun Pharma tripped up by Form 483 at Dadra unit
• April 27, 2017 Daiichi Sankyo to invest $135M in ADC manufacturing expansion
• April 27, 2017 Amid sales growth, Roche plans defense from biosimilar threats
• April 26, 2017 Q1 Earnings Preview: AbbVie, AstraZeneca, BMS, Celgene, Roche, Sanofi
• April 26, 2017 Medicines Co. charts ambitious late-stage tests for heart drug
• April 25, 2017 FDA busts 14 companies for selling bogus cancer cures
• April 25, 2017 Lilly gets lift from new drugs, but baricitinib setback hangs over revenue growth
• April 25, 2017 Cancer immunotherapy works, but how to find which patients will benefit?
• April 24, 2017 Biogen, BioMarin secure orphan drug endorsements in Europe
• April 24, 2017 Q1 Earnings Preview: Novartis, Lilly, Biogen, GSK, Amgen
• April 20, 2017 Biopharma opening up to new ways of partnering on R&D
• April 19, 2017 Theranos pays $4.65M to refund cost of blood tests in Arizona
• April 19, 2017 Former Dendreon CEO debuts new public company in reverse merger
• April 18, 2017 Pharma bellwether J&J not worried about drug pricing for specialty meds
• April 17, 2017 Bristol-Myers taps Danish biotech in NASH biomarker deal
• April 13, 2017 GE acquires British cold chain specialist, deepening cell therapy push
• April 13, 2017 FDA warns Teva over violations at China plant
• April 13, 2017 University of California appeals patent setback, extending CRISPR fight
• April 12, 2017 Biotech calls on 'Poop Troop' to drive constipation awareness
• April 12, 2017 SV Health secures $400M for new life sciences venture fund
• April 11, 2017 Cancer combos key to AstraZeneca success, but rivals have long lead
• April 10, 2017 In familiar routine, ICER finds rheumatoid arthritis drugs overpriced
• April 10, 2017 5 trends shaping rare disease drug development
• April 7, 2017 FDA shoots down Merck's bid to expand Januvia label
• April 6, 2017 Indoco Remedies handed FDA warning letter
• April 6, 2017 PhRMA takes shot at payers in drug pricing war
• April 5, 2017 Scott Gottlieb commits to defend FDA's 'gold standard' for drug reviews
• April 5, 2017 AACR recap: IDOs under the microscope
• April 4, 2017 AACR: NewLink's IDO data shows promise, but is it enough?
• April 3, 2017 AACR: Incyte hedges bet on combo strategy
• April 3, 2017 AACR: Busy start for Bristol-Myers Squibb's Opdivo
• April 2, 2017 CAR-T race heats up as Kite, Novartis complete filings to FDA
• March 30, 2017 Warp Drive Bio teams up with GSK, taking aim at 'undruggable' targets
• March 30, 2017 Agenus trims staff, narrows focus in restructuring
• March 30, 2017 Drug prices continue to climb, but who's to blame?
• March 29, 2017 GSK breathes sigh of relief as Mylan Advair copy rejected
• March 29, 2017 Vertex boosted by strong trial data for next-gen CF drug
• March 29, 2017 AACR preview: IDO1, CDK 4/6 and cancer combos
• March 28, 2017 In twisting patent fight, CRISPR Therapeutics scores win in Europe
• March 27, 2017 Alexion taps ex-Baxalta chief as new CEO
• March 24, 2017 Lilly touts $850M manufacturing investment as CEO stumps for tax reform
• March 23, 2017 Control over production data still tripping up foreign drug manufacturers with FDA
• March 23, 2017 Valeant hopes for August approval of eye drug
• March 23, 2017 J&J, GSK pull ads from YouTube amid display concerns
• March 22, 2017 Biogen staves off patent challenge to blockbuster MS drug
• March 20, 2017 Bristol-Myers and Pfizer's Eliquis outperforms rivals versus warfarin
• March 20, 2017 Phase 3 win moves Lilly's breast cancer drug closer to market
• March 20, 2017 Real world study shows cardiovascular benefit to SGLT2 drugs
• March 17, 2017 Medicines Co. hits mark in ORION, plans PCSK9 Phase 3
• March 17, 2017 Amgen's Repatha shows CV benefit, but falls short of expectations
• March 16, 2017 FDA warns two manufacturers from China, India for GMP lapses
• March 16, 2017 Takeda teams up with venture firm on drug discovery unit
• March 16, 2017 Under fire, Marathon offloads Duchenne drug to PTC for $140M
• March 14, 2017 AstraZeneca staves off Tesaro threat to PARP crown
• March 14, 2017 Allergan taps CRISPR biotech Editas in eye care deal
• March 13, 2017 Novartis locks up Kisqali approval, eyes Pfizer's lead
• March 13, 2017 Mylan clears way for biosimilar Herceptin launch in US
• March 10, 2017 Trump taps Scott Gottlieb to head FDA
• March 10, 2017 Radius shares slide after FDA delays decision on bone drug
• March 9, 2017 Nicox resubmits eye drug to FDA after manufacturing setback
• March 9, 2017 Indian drugmaker slammed for repeated GMP failures
• March 9, 2017 Trump 'enthusiastic' about drug price negotiation, lawmakers say
• March 8, 2017 Despite hype, still much to uncover about immunotherapy
• March 7, 2017 MS drugs too expensive, ICER says
• March 7, 2017 Pressure builds on Marathon over orphan drug price
• March 6, 2017 Changes to MYSTIC could set AstraZeneca up for success
• March 6, 2017 Vertex fine tunes CF portfolio with Concert deal
• Feb. 28, 2017 Industry Pulse: Who's spending on R&D?
• Feb. 24, 2017 Merck writes off $2.9B as new hep C reality blooms
• Feb. 23, 2017 Pharma CEOs sign on to letter urging tax reform
• Feb. 23, 2017 Safety concerns reemerge for Roche hemophilia drug
• Feb. 22, 2017 Harvard Pilgrim bets on value-based drug payments with new deals
• Feb. 21, 2017 Gilead snaps up Sarepta's priority review voucher for $125M
• Feb. 16, 2017 FDA warns another Japanese drug manufacturer over GMP flaws
• Feb. 16, 2017 Are commercial prospects limited for Valeant's Siliq?
• Feb. 15, 2017 Broad Institute notches win in CRISPR patent battle
• Feb. 15, 2017 Merck scraps late-stage study of Alzheimer's candidate
• Feb. 13, 2017 Marathon presses pause on Emflaza launch after pricing pushback
• Feb. 13, 2017 5 trends being impacted by biomarkers
• Feb. 13, 2017 Liquid biopsies: The next frontier in cancer?
• Feb. 10, 2017 Sanofi confident in case to overturn Praluent ban
• Feb. 9, 2017 Regeneron, Sanofi win reprieve from court ban on Praluent
• Feb. 8, 2017 Sanofi pins hopes on immunology as Lantus sales fade
• Feb. 6, 2017 Teva CEO out, board chairman steps in as interim chief
• Feb. 6, 2017 Innate's cancer immunotherapy falls short in Phase 2
• Feb. 2, 2017 FDA warns Italian drug manufacturer for quality lapses
• Feb. 2, 2017 Trump pushes pharma to boost drug production in US
• Jan. 31, 2017 Pfizer counts on Ibrance as Prevnar sales slip
• Jan. 31, 2017 Pfizer's Read sees positives for industry under Trump
• Jan. 31, 2017 Insulin drugmakers sued for inflating prices
• Jan. 30, 2017 Merck ups pricing transparency amid industry ad blitz
• Jan. 26, 2017 Earnings Preview: Merck set to solidify I/O lead, Sanofi still looking for deals and more
• Jan. 26, 2017 Intrexon picks up struggling GenVec to build delivery tech
• Jan. 26, 2017 On the defensive, Bristol faces down I/O competition
• Jan. 26, 2017 J&J seals $30B deal for Actelion
• Jan. 25, 2017 Novartis aims to gain ground on I/O leaders
• Jan. 25, 2017 As Trump moves to repeal, J&J says preserve some of ACA
• Jan. 24, 2017 Anthem limits coverage for Biogen's new SMA drug
• Jan. 24, 2017 J&J earnings disappoint, with no word on Actelion deal
• Jan. 23, 2017 Endo reaches deal with FTC over pay-for-delay allegations
• Jan. 23, 2017 7 companies to know in the emerging biosimilars field
• Jan. 23, 2017 Actelion misses goal in study, but takeover talks likely unaffected
• Jan. 23, 2017 Biosimilars: What's in a name?
• Jan. 20, 2017 Bristol-Myers nixes hopes of early filing for Opdivo combo
• Jan. 19, 2017 Earnings preview: 7 biopharmas to watch
• Jan. 19, 2017 FDA details thinking on off-label communications
• Jan. 18, 2017 Chinese API supplier lands in hot water with FDA
• Jan. 18, 2017 Cellceutix fires back against short-seller accusations
• Jan. 18, 2017 FDA spells out expectations on biosimilar interchangeability
• Jan. 17, 2017 Why Jay Bradner thinks Novartis can recharge drug discovery
• Jan. 17, 2017 Supreme Court to review key biosimilar dispute
• Jan. 12, 2017 FDA issues long-awaited guidance on biosimilar naming
• Jan. 12, 2017 Kite confident as CAR-T readout nears
• Jan. 11, 2017 NCI launches new cancer drug formulary to speed combo trials
• Jan. 11, 2017 JPM: Day 2 round-up
• Jan. 10, 2017 JPM: Valeant sells off Dendreon, skincare brands for $2.1B
• Jan. 9, 2017 JPM: Vertex stakes out cautious 2017 forecasts
• Jan. 8, 2017 JPM: Ipsen snatches up Merrimack's Onivyde for $575M
• Jan. 6, 2017 Judge hands Amgen major patent victory over PCSK9 rivals
• Jan. 5, 2017 FDA to drugmakers: Don't let manufacturing lead to rejection
• Jan. 5, 2017 Alexion faults tone at top, management pressure in Soliris investigation
• Jan. 4, 2017 Amgen notches another win in patent dispute with Sanofi, Regeneron
• Jan. 4, 2017 Tiny Rana makes a play for mRNA with Shire deal
• Jan. 3, 2017 Gates Foundation invests $50M in Intarcia for anti-HIV work
• Dec. 29, 2016 Threat grows for biologics makers as biosimilars take root
• Dec. 24, 2016 As R&D returns take a hit, some pharmas are ramping up spending
• Dec. 22, 2016 Teva pays up $520M to settle bribery charges
• Dec. 22, 2016 Vitality secures approvals for cannabinoid facility
• Dec. 22, 2016 A rough year for biotech IPOs
• Dec. 21, 2016 FDA warns drugmakers on misleading marketing
• Dec. 21, 2016 Incyte puts up $200M in bispecifics deal with Merus
• Dec. 20, 2016 Allergan picks up regenerative med company for $2.9B
• Dec. 20, 2016 Conatus soars on Novartis deal
• Dec. 19, 2016 Editas locks down rights to add-on CRISPR tech
• Dec. 19, 2016 Nasdaq shuffles biotech index ranks, highlighting 2016 hits, misses
• Dec. 16, 2016 Ophthotech shrinks staff in wake of Fovista setback
• Dec. 16, 2016 CRISPR biotechs band together in IP pact
• Dec. 15, 2016 20 states sue 6 generic drugmakers over price fixing
• Dec. 15, 2016 Biogen cuts jobs in MA manufacturing slimdown
• Dec. 14, 2016 First charges come in generic price-fixing probe
• Dec. 14, 2016 Sanofi, Celgene flagged for misleading DTC ads
• Dec. 13, 2016 Bristol-Myers plans R&D overhaul, site shutdowns
• Dec. 13, 2016 Cempra makes CEO change ahead of FDA decision
• Dec. 12, 2016 Armed with IPO cash, CRISPR biotechs grow gene-editing tech
• Dec. 12, 2016 Alexion CEO, CFO out amid Soliris investigation
• Dec. 12, 2016 Purdue lands rights to psoriasis drug in diversification deal
• Dec. 9, 2016 Biogen boosted by early Alzheimer's data
• Dec. 8, 2016 Former pharma execs arrested in bribery scheme
• Dec. 8, 2016 Sun Pharma faces new worries at key Halol plant
• Dec. 8, 2016 'Cures' clears Senate in 94-5 vote
• Dec. 7, 2016 Pfizer hit with record fine in UK for drug price hike
• Dec. 7, 2016 AbbVie breast cancer drug falls short in Phase 2
• Dec. 6, 2016 Sage locks in regulatory path for postpartum depression drug
• Dec. 6, 2016 Kite begins march to market
• Dec. 5, 2016 Juno turns to JCAR017 amid Rocket setback
• Dec. 5, 2016 Alnylam scores ASH win in hemophilia
• Dec. 5, 2016 Novartis forges ahead with lead CAR-T
• Dec. 2, 2016 Eli Lilly, Boehringer secure CV label for Jardiance
• Dec. 1, 2016 House passes 'Cures' in overwhelming vote
• Nov. 30, 2016 Alnylam touts hemophilia drug's edge over Roche rival
• Nov. 30, 2016 Arrowhead nixes clinical pipeline, trims staff
• Nov. 30, 2016 ASH preview: CAR-Ts, mixed results and pipeline progress
• Nov. 28, 2016 Recro Pharma notches second Phase 3 win for pain drug
• Nov. 23, 2016 Juno halts CAR-T trial after new patient deaths
• Nov. 22, 2016 AstraZeneca restarts halted durvalumab trials
• Nov. 21, 2016 Halozyme falls after AbbVie nixes partnered program
• Nov. 17, 2016 Ex-Valeant exec arrested in Philidor kickback scheme
• Nov. 16, 2016 Ex-FDA official settles insider trading charges
• Nov. 16, 2016 Boxed warning added to label of Bayer's Essure
• Nov. 15, 2016 Data in hand, The Medicines Co. speeds PCSK9 plans
• Nov. 15, 2016 Costs for many Medicare drugs continue steady rise
• Nov. 14, 2016 Dynavax drops on FDA rejection of hep B vaccine
• Nov. 11, 2016 CHMP decision round-up; PTC wins reprieve
• Nov. 10, 2016 Valeant hit with another FDA warning letter
• Nov. 10, 2016 As rival surges forward, Juno touts CAR-T pipeline
• Nov. 9, 2016 FDA invites pharma input in off-label debate
• Nov. 8, 2016 The Medicines Co. abandons heart drug, focus all on PCSK9si
• Nov. 7, 2016 Biogen eyes quick launch for SMA drug
• Nov. 7, 2016 Key people to know in early drug development
• Nov. 7, 2016 Advice to an emerging biotech
• Nov. 7, 2016 5 trends turning biotech toward incubators
• Nov. 3, 2016 Portola broadens AndexXa partnership with Daiichi
• Nov. 2, 2016 Doctors willing to prescribe biosimilars, survey shows
• Nov. 2, 2016 What would a Salix sale do for Valeant?
• Nov. 1, 2016 Shire confident in hemophilia despite looming pricing challenge
• Oct. 31, 2016 Amid pricing scrutiny, Amgen CEO predicts more value-based contracts
• Oct. 31, 2016 Third Rock Ventures secures $616M in new biotech fund
• Oct. 27, 2016 Czech drugmaker hit with FDA warning letter
• Oct. 27, 2016 Continuing M&A spree, Allergan picks up Motus for $200M
• Oct. 26, 2016 The Medicines Co. moves cholesterol drug forward as sales fall
• Oct. 26, 2016 Humana to cover Sarepta's DMD drug with caveats
• Oct. 25, 2016 Lilly says complete Sola failure unlikely
• Oct. 24, 2016 Merck cements advantage in I/O with first-line approval
• Oct. 24, 2016 Aduro hit with partial hold, sending shares spiraling
• Oct. 21, 2016 Alkermes surges on antidepressant success
• Oct. 20, 2016 Dimension beefs up AAV manufacturing
• Oct. 20, 2016 Single placebo response derails Rigel study
• Oct. 19, 2016 Merck lays groundwork for biosimilar push
• Oct. 19, 2016 CAR-T ready for flight, says Kite
• Oct. 18, 2016 Earnings guide: A preview of 9 big pharmas in Q3
• Oct. 18, 2016 Medicines Co. scores positive results for PCSK9 drug
• Oct. 17, 2016 FDA snubs PTC appeal for Duchenne drug
• Oct. 16, 2016 Bluebird touts upgrades to gene therapy
• Oct. 13, 2016 Insulin makers become casualties of pricing war
• Oct. 12, 2016 AstraZeneca halts asthma study in blow to Synairgen
• Oct. 11, 2016 Merck inks pay-for-performance deal to boost diabetes drugs
• Oct. 10, 2016 Takeda broadens oncology pipeline with Crescendo deal
• Oct. 10, 2016 Downfall of a unicorn: How Theranos fell apart
• Oct. 9, 2016 Major US insurer snubs Sarepta's Duchenne drug
• Oct. 6, 2016 Theranos shuts down labs, lays off 340
• Oct. 5, 2016 Novartis shakes up R&D, closing down two biologics units
• Oct. 4, 2016 Sarepta steps up DMD dealmaking
• Oct. 3, 2016 Biosimilars emerge in US, but what to call them?
• Oct. 3, 2016 AstraZeneca furthers sell-off strategy with new deal
• Sept. 30, 2016 Regeneron slips on trial setback for Eylea combo
• Sept. 29, 2016 FDA cites Chinese manufacturers for GMP lapses
• Sept. 29, 2016 Novartis, Amgen score Phase 3 win for migraine drug
• Sept. 29, 2016 Will staff cuts help Novo stay competitive?
• Sept. 28, 2016 Boehringer gets option to buy in I/O deal
• Sept. 27, 2016 Kite bolsters lead with positive CAR-T data
• Sept. 26, 2016 Pfizer nixes split plans, opts to remain one company
• Sept. 23, 2016 Indivior stumbles as US states file antitrust suit
• Sept. 22, 2016 FDA approval in hand, Sarepta plans for future studies
• Sept. 22, 2016 Moderna lifts curtain on manufacturing plant plans
• Sept. 22, 2016 Gilead shutters study for anti-MMP9 drug
• Sept. 20, 2016 Allergan pays steep premium for Tobira and NASH drugs
• Sept. 19, 2016 Drama at FDA: 5 things to know about the Sarepta approval
• Sept. 19, 2016 Sarepta skyrockets as FDA approves DMD drug
• Sept. 19, 2016 Valeant: rebates on heart drugs are coming
• Sept. 16, 2016 Novavax short on options after vaccine fails trial
• Sept. 15, 2016 Eisai ramps up precision med efforts with new unit
• Sept. 15, 2016 Lonza builds out gene therapy offerings
• Sept. 15, 2016 Novo pulls 71,000 kits of glucagon med from US market
• Sept. 15, 2016 AcelRx stock jumps after trial success
• Sept. 14, 2016 UN group urges 'de-linkage' of R&D costs from drug prices
• Sept. 14, 2016 BIO blames insurers in pushback on drug pricing
• Sept. 14, 2016 Roche bolsters evidence for MS drug Ocrevus
• Sept. 13, 2016 Irish startup secures $17M Series A
• Sept. 12, 2016 Generic drugmaker under federal pricing probe
• Sept. 12, 2016 Aveo halts study of lung cancer drug
• Sept. 12, 2016 Horizon adds rare disease drugs in $800M Raptor deal
• Sept. 12, 2016 CRISPR closes in on $90M IPO
• Sept. 9, 2016 J&J pushes forward with hep C triple-combo
• Sept. 9, 2016 Allergan highlights new drug potential
• Sept. 8, 2016 Fresh off new funding, Moderna plans new manufacturing plant
• Sept. 8, 2016 FDA renews ban on Indian drugmaker after fresh violations
• Sept. 8, 2016 Bluebird proceeds with late-stage trial after key improvement
• Sept. 8, 2016 Gilead comments on split rumors
• Sept. 7, 2016 Tonix shelves fibromyalgia plans after Phase 3 miss
• Sept. 7, 2016 Karyopharm tees up filing for multiple myeloma drug
• Sept. 6, 2016 Jazz subsidiary warned over misbranding of cancer drug
• Sept. 6, 2016 Allergan CEO disavows 'predatory pricing'
• Sept. 6, 2016 Flush from Pfizer deal, Medivation execs set to cash in
• Sept. 2, 2016 Momenta pulls the plug on pancreatic cancer drug
• Sept. 1, 2016 Sunovion snaps up Cynapsus in $624M deal
• Sept. 1, 2016 In wake of generics deal, Teva to close New York plant
• Sept. 1, 2016 Theranos stumbles in efforts to sell Zika test: report
• Sept. 1, 2016 Gilead hit with patent suit over hepatitis C drugs
• Sept. 1, 2016 Roche's Tecentriq ready to compete in lung cancer
• Aug. 31, 2016 Weighing in on EpiPen, PhRMA calls for reforms at FDA
• Aug. 31, 2016 Novartis breaks up CAR-T unit in major shift
• Aug. 30, 2016 Novartis wins US approval for biosimilar Enbrel
• Aug. 30, 2016 Looking past FDA snub, Portola touts new Andexxa data
• Aug. 30, 2016 Trial failure dashes Vectura's hopes for wider use of asthma drug
• Aug. 30, 2016 Stada elects new chairman after activist pressure
• Aug. 29, 2016 Moderna reels in $450M in new funding
• Aug. 28, 2016 Biosim threat stiffens for Roche's Herceptin
• Aug. 26, 2016 Mallinckrodt sharpens specialty pharma focus
• Aug. 26, 2016 Theranos planning appeal of federal penalties
• Aug. 25, 2016 Sagent recalls injectable antibiotic
• Aug. 25, 2016 Denali secures $130M in new funding, reveals R&D plans
• Aug. 25, 2016 FDA unexpectedly snubs Amgen drug
• Aug. 24, 2016 Pfizer continues dealmaking with antibiotics buy
• Aug. 24, 2016 With PDUFA date for rucaparib set, Clovis eyes rebound
• Aug. 16, 2016 MI Labs to biotechs: Call us home
• Aug. 16, 2016 OncoGenex scrambles after trial fail
• Aug. 16, 2016 Aurinia succeeds, but safety concerns loom
• Aug. 15, 2016 Veteran CEO of German drugmaker Stada resigns
• Aug. 15, 2016 Chinese regulators advance overhaul of drug manufacturing
• Aug. 15, 2016 AcelRx meets goal in Phase 3, but stock slips
• Aug. 15, 2016 Gilead can recoup legal fees from Merck, judge says
• Aug. 12, 2016 Drug pricing studies anger industry, ICER pushes back
• Aug. 11, 2016 Valeant tumbles on report of fraud investigation
• Aug. 10, 2016 NIH shuts down facility used to produce drugs for clinical trials
• Aug. 9, 2016 Pfizer temporarily shutters Indian facility after inspections
• Aug. 9, 2016 Seizing CAR-T lead, Kite readies commercial-scale manufacturing
• Aug. 9, 2016 Editas continues to expand CRISPR capabilities with new deal
• Aug. 8, 2016 Kite steps up plans for leading CAR-T, putting pressure on Juno
• Aug. 8, 2016 Novo Nordisk sees pricing challenges 'intensifying'
• Aug. 5, 2016 Despite trial restart, Juno pushes back launch timeline for CAR-T therapy
• Aug. 5, 2016 Bristol-Myers' Opdivo fails key lung cancer study, stocks ricochet
• Aug. 4, 2016 Pfizer cuts 151 jobs at New York plant
• Aug. 4, 2016 Chinese drug manufacturer lies to FDA, promptly gets banned
• Aug. 4, 2016 Gilead: 'We stand behind the pricing of our therapies'
• Aug. 3, 2016 Takeover rumors juice Biogen stock, but fade fast
• Aug. 2, 2016 Amgen secures rights to cancer immunotherapy from biotech Advaxis
• Aug. 2, 2016 Theranos founder Holmes touts new tech despite unanswered questions
• Aug. 1, 2016 Biogen snaps up rights to neuromuscular disease drug after trial success
• Aug. 1, 2016 GSK, Verily launch $715 million bet on bioelectronic medicines
• July 29, 2016 Higher Humira sales lift AbbVie in Q2
• July 29, 2016 Merck's Keytruda continues gains, driving Q2 revenues higher
• July 28, 2016 Bristol-Myers revenues climb on strong Opdivo performance
• July 27, 2016 Amgen boosts sales forecast as Q2 profits jump
• July 27, 2016 US regulators clear Teva, Allergan generics deal
• July 27, 2016 TauRx Alzheimer's drug flunks late-stage study
• July 27, 2016 Lilly CEO John Lechleiter to retire by year-end
• July 26, 2016 Health plans slow to adopt new drug value assessments: survey
• July 26, 2016 Lilly blames stiff competition for lower US sales of lung cancer drugs
• July 25, 2016 Gilead trims guidance as Hepatitis C drug sales slip
• July 25, 2016 Alzheon readies Phase 3 study of Alzheimer's drug
• July 25, 2016 AbbVie partners with Bristol-Myers in combo study of cancer drugs
• July 22, 2016 Fresh off Relistor win, Valeant hits FDA roadblock for eye drug
• July 22, 2016 Chinese team to test CRISPR in humans, jumping ahead of planned US study
• July 21, 2016 Swiss group Galencia buys US biotech Relypsa for $1.5 billion
• July 21, 2016 Biogen CEO George Scangos to step down
• July 21, 2016 Roche sales buoyed by cancer drugs
• July 20, 2016 Federal court thwarts AstraZeneca efforts to block Crestor copies
• July 20, 2016 Valeant wins backing of FDA panel for psoriasis drug
• July 19, 2016 Bristol-Myers settles for $30 million over California kickback claims
• July 19, 2016 Ziopharm says patient death unrelated to gene therapy
• July 19, 2016 Novartis doubles down on new drugs as sales slump for top cancer med
• July 19, 2016 FDA: Flood of orphan drug applications slowing review process
• July 18, 2016 Roche blood cancer drug falls short in late-stage study
• July 15, 2016 With new additions, PhRMA opens door to generics drugmaker Teva
• July 15, 2016 FDA staff raises safety concerns for Valeant psoriasis drug
• July 14, 2016 Why Allergan thinks an 'open science' approach can help it develop new antibiotics
• July 14, 2016 Amgen partners with Daiichi to market biosimilars in Japan
• July 13, 2016 Large Valeant investor sold off remaining stake last quarter
• July 12, 2016 Juno restarts suspended CAR-T trial after FDA lifts clinical hold
• July 12, 2016 Merck trims research jobs at three sites, shifts drug discovery focus
• July 12, 2016 Sage soars after small study of postpartum depression drug shows benefit
• July 11, 2016 Cancer drug could benefit Parkinson's patients, study shows
• July 11, 2016 Facing major penalties, Theranos could be forced to change business
• July 8, 2016 FDA staff backs Amgen biosim of AbbVie's Humira
• July 8, 2016 Theranos founder banned from blood-testing business
• July 7, 2016 Juno CAR-T trial halted by FDA after three patient deaths
• July 7, 2016 AbbVie bet on Ablynx gets boost after arthritis drug shows promise
• July 6, 2016 Pfizer pledges to disclose risks of opioid addiction
• July 5, 2016 Federal appeals court reaffirms biosimilar launch rules
• July 5, 2016 Medivation enters takeover talks with Sanofi after rejecting new bid
• July 5, 2016 UK cost agency knocks back Bristol-Myers' Opdivo in kidney cancer
• July 5, 2016 Bristol-Myers buys Cormorant Pharma, eyes cancer combo potential
• July 1, 2016 AstraZeneca sells off dermatology drug rights to LEO Pharma
• June 30, 2016 Major trade group slams 'misleading' analysis of drug prices
• June 29, 2016 Tesaro soars after ovarian cancer drug meets Phase 3 goal
• June 29, 2016 In narrow vote, FDA panel supports heart benefit claim for Lilly diabetes drug
• June 28, 2016 VA teams up with IBM's supercomputer Watson to expand precision medicine
• June 28, 2016 Harvard Pilgrim inks pay-for-performance deals with Novartis, Eli Lilly
• June 28, 2016 Gilead wins FDA nod for pan-genotypic Hep C drug
• June 28, 2016 Pfizer to open first Asia biotech center in China
• June 28, 2016 Novartis jumps into bi-specific antibody space with $150 million Xencor deal
• June 27, 2016 FDA halts testing of Regulus' Hep C drug, sending shares into tailspin
• June 27, 2016 GW Pharma shares jump on Phase 3 data for cannabis-based drug
• June 27, 2016 Sanofi, Boehringer trade business units in $25 billion swap
• June 24, 2016 Teva seals deal to market copy of AstraZeneca diabetes drug
• June 24, 2016 Brexit vote creates new uncertainty for UK, EU pharma industry
• June 23, 2016 Epizyme partners with Roche to test cancer drug combo
• June 23, 2016 Pfizer plans to close Colorado production facility
• June 23, 2016 AstraZeneca writes off $80 million after US authorities say nasal flu vaccine ineffective
• June 22, 2016 First human study of CRISPR approved by federal panel
• June 21, 2016 Startup biotech Homology Med aims to 'leapfrog' CRISPR competitors
• June 21, 2016 Teva, Allergan continue to shed assets with $586 million sale to Impax
• June 21, 2016 Takeda begins field testing norovirus vaccine
• June 20, 2016 NIH turns down request to override cancer drug patent
• June 20, 2016 Doubling down on biosimilars, Novartis plans five launches by 2020
• June 17, 2016 NIH panel to review proposal for first in human test of CRISPR
• June 16, 2016 Pfizer begins construction on $200 million biologics plant in MA
• June 16, 2016 Merck's Keytruda beats out chemotherapy in lung cancer study
• June 15, 2016 Facing legal troubles and declining sales, Aegerion to merge with Canadian QLT
• June 15, 2016 Marathon Pharma latest company to try for approval of Duchenne drug
• June 14, 2016 Shire buys rights to Pfizer bowel disease drug
• June 14, 2016 FDA warns of kidney risks for diabetes drugs from Janssen, AstraZeneca
• June 14, 2016 Former Dendreon CEO leads Alpine Immune to $48 million financing
• June 9, 2016 Report: Oncology drove record pharma dealmaking in 2015
• June 8, 2016 Small biotech Accera reinvents itself, takes aim at Alzheimer's treatment
• June 7, 2016 FDA asks Sarepta for more data on muscular dystrophy drug
• June 5, 2016 AbbVie lung cancer drug shows promise, but has high expectations to meet
• June 2, 2016 With eye to growing Chinese market, Novartis opens major R&D hub in Shanghai
• June 2, 2016 Global cancer drug spending rises, set to surpass $150 billion by 2020
• June 1, 2016 FDA warns another Indian API supplier on manufacturing lapses
• June 1, 2016 Activist investor Icahn acquires large stake in Allergan
• June 1, 2016 Despite stock plunge, former Valeant CEO to collect $9 million in severance pay
• May 31, 2016 BioMarin ends Duchenne program, withdraws EU application for drisapersen
• May 31, 2016 Intercept shares climb on FDA approval of liver drug
• May 31, 2016 Jazz Pharma snaps up leukemia drug with $1.5 billion deal for Celator
• May 27, 2016 EMA knocks back multiple myeloma drug from Takeda
• May 27, 2016 Roche's Gazyva notches early trial success
• May 27, 2016 FDA rejects AstraZeneca hyperkalemia drug, boosting competitor Relypsa
• May 26, 2016 Bristol-Myers attacks cost-effectiveness study of cancer drug
• May 26, 2016 Sanofi diabetes drug wins adcomm support, keeping pace with Novo
• May 25, 2016 Theranos hit with class-action lawsuit over blood-testing claims
• May 25, 2016 Sarepta shares jump after FDA delays decision on Duchenne drug
• May 24, 2016 Despite recent R&D setbacks, Lilly aims to launch 20 new drugs by 2023
• May 24, 2016 Janssen's multiple myeloma drug passes muster in Europe
• May 24, 2016 After setback, GSK's Breo gets boost from real-world data
• May 24, 2016 Eyeing US market, Samsung applies for approval of biosimilar Remicade
• May 23, 2016 EMA removes warning from Pfizer smoking cessation drug
• May 23, 2016 Ahead of key panel vote, FDA staff raises concerns over Novo diabetes drug
• May 19, 2016 Immunotherapies from Merck and Bristol-Myers help extend life, new data shows
• May 19, 2016 Theranos corrects two years of test results: WSJ
• May 19, 2016 Roche to shutter Clarecastle plant after it can't find buyer
• May 19, 2016 Roche's much-anticipated immontherapy wins early approval for bladder cancer
• May 18, 2016 New patent threat looms for AbbVie's blockbuster Humira
• May 17, 2016 Bristol-Myers extends lead with new Opdivo indication
• May 17, 2016 Novartis splits drugs unit, pharma chief to depart
• May 17, 2016 AstraZeneca asthma drug clears phase 3 studies, boosting respiratory pipeline
• May 16, 2016 Biogen unveils gene therapy collaboration with UPenn experts
• May 16, 2016 After criticism, Valeant details plans for hospital discounts on heart drugs
• May 16, 2016 With generics deal pending, Teva's Europe portfolio attracts buyers
• May 16, 2016 Pfizer adds eczema drug in $5.2 billion deal for Anacor
• May 12, 2016 Aegerion to plead guilty to misbranding cholesterol drug, will pay $40 million
• May 12, 2016 After shutting down cancer drug, Clovis now facing government investigations
• May 12, 2016 Baxter reportedly top suitor for Indian injectables maker
• May 12, 2016 Amid losses, Endo plans cutbacks at Par manufacturing facilities
• May 12, 2016 U.K. cost agency rejects Bristol-Myer's Opdivo for lung cancer
• May 12, 2016 Theranos president to leave company as federal scrutiny continues
• May 11, 2016 Colombian diplomat warns of fallout from Novartis patent battle
• May 11, 2016 Drugmakers hit with federal investigations of PBM contracts
• May 10, 2016 India awards patent to Gilead's Sovaldi
• May 10, 2016 Allergan plans $10 billion stock buyback as it waits for Teva cash
• May 10, 2016 FDA flags potential safety risk for Lilly antipsychotic drug
• May 10, 2016 'The sharks are circling:' 5 insights from the Valeant documents
• May 9, 2016 Medicines Co. sells off cardiovascular drugs to Italy's Chiesi
• May 9, 2016 Lower sales of generic drugs weigh on Teva's first-quarter revenue
• May 6, 2016 As new CEO takes over, Valeant forms committee to oversee drug pricing
• May 6, 2016 As Big Pharma circles, Medivation makes case for independence
• May 5, 2016 FDA reaches agreement with Xellia on troubled manufacturing plant
• May 5, 2016 Biogen spinoff set to build out hemophilia pipeline
• May 5, 2016 Sanofi threatens Medivation board with hostile bid
• May 5, 2016 Merck sales hit by generic competition in US, Europe
• May 4, 2016 Report: Pfizer considering takeover offer for sought-after Medivation
• May 3, 2016 Israeli pharma company provides rare disease drug for free after it can't find patients
• May 3, 2016 Pfizer revenues surge as vaccines, new drugs rack up sales
• May 3, 2016 Boosting focus on neurology, Biogen to spin off hemophilia business
• May 2, 2016 Eagle Pharma hits FDA with lawsuit after cancer drug denied orphan exclusivity
• May 2, 2016 Gene editing biotech Homology Med launches with $44 million in financing
• May 1, 2016 Federal judge reopens high-stakes patent case between Merck and Gilead
• April 29, 2016 As profits drop, AstraZeneca trims costs and sharpens focus on R&D
• April 29, 2016 With CEO Pearson set to bow out, Valeant files much-delayed annual report
• April 28, 2016 As new drugs take hold, Lilly ramps up R&D spend
• April 28, 2016 Adding to changes at top, Valeant reportedly set to turn over board
• April 28, 2016 Sanofi pressures Medivation to take $9.3 billion bid
• April 27, 2016 Valeant officials apologize to Senate panel for steep price hikes
• April 27, 2016 Valeant increased prices too aggressively, CEO expected to tell Senate panel
• April 26, 2016 FDA demands additional studies for Catalyst's firdapse
• April 26, 2016 Seven New York insurers end restrictions on coverage for hepatitis C drugs
• April 26, 2016 New drug sales boost Lilly revenue, yet profits tumble
• April 25, 2016 Despite efforts of advocates, FDA panel votes against Sarepta's Duchenne drug
• April 25, 2016 Valeant names ex-Perrigo chief Joseph Papa as CEO
• April 22, 2016 Inside the development of Venclexta, AbbVie's new leukemia drug
• April 22, 2016 Adding to cosmetic portfolio, Allergan buys Topokine for $85 million
• April 22, 2016 AstraZeneca launches massive drug discovery effort, aims to sequence 2 million genomes
• April 21, 2016 Continuing scrutiny, FDA hits Sri Krishna with warning over 'serious' data violations
• April 21, 2016 China investigates 3 drugmakers for manufacturing violations, orders recall
• April 21, 2016 Novartis income falls as key cancer drug battles generic competition
• April 21, 2016 Bluebird Bio gene therapy sees encouraging early results in treatment of rare brain disease
• April 19, 2016 NIH suspends work at two facilities, including T-cell research
• April 19, 2016 Bristol-Myers' Opdivo shows promise in head, neck cancers
• April 19, 2016 Roche beats Q1 expectations on strong oncology sales
• April 19, 2016 With new studies, Boehringer and Lilly to pit diabetes drug against heart failure
• April 19, 2016 Theranos reportedly facing new federal investigations
• April 18, 2016 Bristol-Myers' Opdivo gets boost from long-term survival data
• April 17, 2016 Review of NCI facilities halts patient enrollment in Kite T-cell studies
• April 17, 2016 Report: AstraZeneca considering bid for cancer biotech Medivation
• April 15, 2016 Further downgrade to Valeant ratings reportedly could trigger forced selling
• April 14, 2016 Swiss company Lonza Group seeking to acquire CRO Catalent: report
• April 14, 2016 FDA advocates for adoption of speedier drug manufacturing technique
• April 14, 2016 Report: U.S. drug spending hit $310 billion last year
• April 13, 2016 Regulator proposes 2-year ban of Theranos founder Elizabeth Holmes
• April 13, 2016 Biosimilars gain momentum — and pharma leaders are noticing
• April 12, 2016 Large bondholder hits Valeant with default notice
• April 12, 2016 Clovis' lung cancer drug fails to impress FDA panel
• April 12, 2016 Japanese genomic analysis characterizes liver cancer into six types
• April 11, 2016 CRISPR biotech Intellia strikes licensing deal with Regeneron, readies IPO
• April 11, 2016 Life after Shkreli: KaloBios promises affordable drugs, no 'price gouging'
• April 11, 2016 AbbVie and Roche team wins FDA approval for leukemia drug
• April 11, 2016 Roche's anti-PDL1 immunotherapy granted fast track status
• April 10, 2016 Valeant board asks CEO Pearson to cooperate with Senate panel subpoena
• April 8, 2016 Amid questions on accuracy of blood tests, Theranos bulks up its medical board
• April 8, 2016 After Alzheimer's drug passes safety review, AstraZeneca and Lilly push into Phase 3
• April 7, 2016 Inspections by FDA hurting Indian drug exports, says Dr. Reddy's chairman
• April 7, 2016 Why partnerships are crucial for pushing vaccine R&D forward
• April 7, 2016 Allergan snaps up rights to Alzheimer's drugs in deal with Heptares
• April 7, 2016 Lenders give Valeant a reprieve, agree to extend deadline for filing annual report
• April 6, 2016 After merger with Pfizer implodes, Allergan's acquisition options open up
• April 6, 2016 Pfizer calls off $160 billion merger with Allergan
• April 5, 2016 Remicade copy clears FDA, becomes second biosim to win approval in U.S.
• April 5, 2016 In phase 3 collaboration, Merck and Pfizer testing PDL1/TKI combo
• April 5, 2016 Valeant panel concludes Philidor investigation, finds no more misstatements
• April 5, 2016 New US inversion rules could wreck Pfizer-Allergan deal
• April 4, 2016 Report: Valeant cuts sales force for female libido drug
• April 4, 2016 Gilead's new HIV formulation continues success with FDA approval of Descovy
• April 4, 2016 Study shows no clinical benefit from Lilly's failed cholesterol drug
• April 3, 2016 GSK gene therapy for rare immune disorder wins EMA approval
• April 1, 2016 Samsung Bioepis' biosim of Remicade clears regulatory hurdle in EU
• April 1, 2016 FTC alleges Endo struck illegal deals to delay release of generic drugs
• April 1, 2016 Canadian securities regulator issues cease trade orders to Valeant management
• March 31, 2016 As aging blockbusters come off patent, new opportunities emerge for biosim manufacturers
• March 31, 2016 In quest to expand diabetes market share, Novo breaks ground on $1.8b U.S. plant
• March 31, 2016 GSK won't file drug patents in low-income countries
• March 30, 2016 Indian drug regulator to begin surprise inspections at manufacturing sites
• March 30, 2016 FTC asks Pfizer, Allergan for more details on proposed mega-merger
• March 30, 2016 With deadline looming, Valeant asks lenders for more time to file report
• March 30, 2016 Cambridge-based Aveo settles fraud charges with SEC for $4 million
• March 29, 2016 FDA panel says benefits outweigh risks for Acadia's Parkinson's drug
• March 29, 2016 Sun Pharma expands presence in Japan with $293 million deal for Novartis drugs
• March 28, 2016 Sanders, other lawmakers urge NIH to consider patent override on cancer drug
• March 28, 2016 New phase 2 data boosts prospects for Alder's migraine drug
• March 28, 2016 Spending on Vertex's Kalydeco consumed 86% of Scottish rare disease fund's budget
• March 27, 2016 Sprout investors reportedly allege Valeant overpriced Addyi
• March 25, 2016 Gilead to pay Merck $200 million in damages for Hep C patents
• March 24, 2016 Patent case in India highlights tensions between public health, protecting innovation
• March 24, 2016 Head of Valeant's largest investor retires as drugmaker's troubles hit fund
• March 23, 2016 A month after FDA spurned DMD drug, PTC laying off 18% of workforce
• March 23, 2016 In major stroke study, AstraZeneca's Brilinta fails to beat aspirin
• March 22, 2016 Merck wins major victory in hep C patent case against Gilead
• March 22, 2016 Eli Lilly's ixekizumab gets green light from FDA
• March 22, 2016 As stock crashed, Valeant's largest shareholder reportedly sold 1.5m shares
• March 22, 2016 In response to crisis, FDA mandates new warnings for opioid painkillers
• March 21, 2016 Citing 'improper conduct,' Valeant attempts to oust former CFO from board
• March 21, 2016 Valeant's Pearson will step down as CEO; Ackman joins Board
• March 20, 2016 U.K. cost regulator confirms final approval for Novartis' Entresto
• March 18, 2016 Johnson & Johnson's psoriasis drug Stelara succeeds in Phase 3
• March 18, 2016 In new deal, Kite Pharma partnering with Roche on cancer immunotherapy
• March 17, 2016 McKesson laying off 1,600 employees
• March 17, 2016 Scientists develop new type of stem cell with only half a genome
• March 17, 2016 Amgen signs 'flexible manufacturing agreement' with CMO Patheon
• March 17, 2016 GSK head Andrew Witty to step down in spring 2017
• March 16, 2016 Jury rules in favor of Amgen in PCSK9 patent fight
• March 16, 2016 After forecast cut, Valeant stock collapses as investors head for the exits
• March 15, 2016 As EMA investigates, Gilead halts six clinical trials of cancer drug
• March 15, 2016 Express Scripts: Growth in overall U.S. drug spending slowed in 2015
• March 15, 2016 Teva's $40.5 billion generics deal with Allergan hits FTC snag
• March 15, 2016 Roche signs potential $1 billion cancer immunotherapy deal with Cambridge biotech
• March 15, 2016 Valeant cuts 2016 revenue projections by $1.5 billion
• March 14, 2016 Amid investor criticism, AstraZeneca considers link between executive pay and revenue goal
• March 11, 2016 Doctors Without Borders moves to block Pfizer patent in India
• March 11, 2016 Sanofi's sarilumab bests blockbuster Humira in Phase 3 study
• March 10, 2016 EC approves Teva's $40.5B deal for Allergan generics arm
• March 10, 2016 House Oversight committee presses Valeant on details of withheld documents
• March 10, 2016 First generic version of Viagra in the U.S. approved by FDA
• March 10, 2016 Death from French drug trial likely due to high doses of compound
• March 10, 2016 Senate bill adding Zika to priority review program highlights R&D incentives
• March 10, 2016 VA broadens Hep C coverage to all veterans, not just the sickest
• March 9, 2016 FDA accepts new Keytruda data, opening door for wider indication
• March 9, 2016 Report: Theranos continued blood tests even as quality checks revealed flaws
• March 9, 2016 Hoping for rebound, Valeant adds three new members to board
• March 9, 2016 US prescription drug spending increases to an estimated $457 billion in 2015
• March 8, 2016 CMS proposes overhaul to Part B drug reimbursement
• March 8, 2016 India will reportedly refrain from issuing compulsory drug licenses
• March 8, 2016 Ending 20-year partnership, Sanofi and Merck close down joint vaccines venture
• March 7, 2016 Bayer, Novartis, Sanofi lose big on Venezuelan bonds
• March 7, 2016 EMA debuts new program to speed up review of innovative drugs
• March 7, 2016 In high-profile failure, Celldex's cancer vaccine crashes in phase 3
• March 7, 2016 AbbVie paying Boehringer $595M upfront to gain access to psoriasis drug
• March 4, 2016 Janssen, AbbVie's Imbruvica approved by FDA for first line treatment of CLL
• March 4, 2016 Moody's downgrades pharma industry outlook, cites lower pricing
• March 4, 2016 UK Autolus reels in £40 million for CAR-T development
• March 4, 2016 Much-anticipated trial shows Novo's Victoza reduces CV risk
• March 3, 2016 Kite, Juno ramping up commercial manufacturing capacity for CAR-T
• March 3, 2016 Valeant dermatology exec resigns, company cites 'personal reasons'
• March 3, 2016 Express Scripts unimpressed by insulin data on Novo's Tresiba
• March 3, 2016 FDA opposes re-authorization of pediatric priority review program: GAO report
• March 2, 2016 Animated drug ads prompt FDA study into effect on consumer behavior
• March 2, 2016 UK cost regulator rejects promising cancer med Imbruvica
• March 1, 2016 Second TAF-based HIV treatment from Gilead wins FDA approval
• March 1, 2016 PhRMA sues to challenge Ohio ballot initiative limiting drug prices
• March 1, 2016 Biotech Exelixis scores $200M from Ipsen for cancer drug rights
• Feb. 29, 2016 Hearings begin in India on validity of Gilead patent for hep C med
• Feb. 29, 2016 On the heels of CEO's return, Valeant under new investigation by the SEC
• Feb. 29, 2016 Amid calls for breakup, Glaxo reportedly begins search for successor to CEO Witty
• Feb. 29, 2016 Valeant's Pearson returns from medical leave, resumes post as CEO
• Feb. 26, 2016 Gilead's new HIV combo drug inches closer to EU approval
• Feb. 25, 2016 DNA sequencer Illumina sues competitor over nanopore patents
• Feb. 25, 2016 European pharma industry warns against 'Brexit,' urges Britain to remain in EU
• Feb. 25, 2016 First human trial of optogenetics to treat blindness set to launch
• Feb. 25, 2016 KaloBios asking bankruptcy court approval to buy rights to Chagas drug
• Feb. 24, 2016 Senate confirms Califf as FDA commissioner by an 89-4 vote
• Feb. 24, 2016 PTC stock falls off a cliff after biotech slapped with FDA 'refusal to file'
• Feb. 24, 2016 7 big pharma companies sign on to Parkinson's development group
• Feb. 23, 2016 How the opioid crisis convinced these senators to oppose advancing Califf's nomination, in charts
• Feb. 23, 2016 FDA chief nominee Califf likely to be confirmed after clearing key Senate vote
• Feb. 23, 2016 CVS reports dramatic drop in Rx spending growth after 2014's double-digit spike
• Feb. 22, 2016 Novartis, Broad researchers find hope in potential gene target for intractable cancers
• Feb. 19, 2016 Sandoz to Supreme Court: Don't let branded drugmakers have extra leg up on biosims
• Feb. 18, 2016 Sun Pharma to seek re-inspection of non-compliant Halol plant
• Feb. 17, 2016 FDA 'refusal to file' letter sends Catalyst tumbling
• Feb. 17, 2016 New, emotional BIO ad highlights innovation in effort push back on pricing critics
• Feb. 17, 2016 Next-gen T-cell cancer therapy hopes buoyed by promising new data
• Feb. 16, 2016 Looking ahead at orphan drugs' future: More breakthroughs, exploding sales
• Feb. 12, 2016 Disappointment for Incyte as phase 3 failure prompts halt on Jakafi solid tumor trials
• Feb. 11, 2016 Update: Sandoz continues biosim streak, acquires rights to Pfizer's Remicade copy in Europe
• Feb. 11, 2016 Report: US CMO market set to rebound as foreign quality concerns grow
• Feb. 11, 2016 From 'hit' to candidate: Inside Sanofi's massive compound sharing agreement with AZ
• Feb. 11, 2016 Imprimis marches on with price cut strategy, will offer cheaper version of Retrophin's kidney stone med
• Feb. 10, 2016 CMS pulls memo detailing possible changes to Medicare's drug reimbursements for docs
• Feb. 10, 2016 Juno CEO, CFO snag bonuses after $1 billion Celgene deal
• Feb. 9, 2016 Novartis strikes rare P4P deals with Aetna & Cigna, will price heart med based on outcomes
• Feb. 8, 2016 Obama asks Congress for $1.8 billion to counter Zika ahead of mosquito season
• Feb. 8, 2016 An Indian biotech is already developing two Zika vaccine candidates
• Feb. 5, 2016 LA county doctor sentenced to 30 years to life for over-prescribing addictive drugs
• Feb. 4, 2016 FDA, Califf to overhaul opioid approval process following intense public pressure
• Feb. 4, 2016 UK to funnel $160 million into clinical research infrastructure
• Feb. 4, 2016 AstraZeneca's potential lung cancer blockbuster nabs EU approval
• Feb. 3, 2016 Gilead hunting for deals as Q4 earnings beat expectations
• Feb. 2, 2016 Damaging House memos reveal calculated drug price increases at Turing, Valeant
• Feb. 2, 2016 Sanofi reportedly planning to cut 600 jobs over 3 years in France
• Feb. 1, 2016 WHO declares Zika a global health emergency, calls for greater collaboration
• Feb. 1, 2016 Valeant hits back at Clinton's 'predatory pricing' accusations
• Jan. 29, 2016 Senators Manchin, Ayotte join growing opposition to Califf FDA nomination
• Jan. 29, 2016 Looking ahead at Lilly's 2016 prospects after a challenging 2015
• Jan. 28, 2016 Pfizer recalls 3 lots of Lyrica after heat damage
• Jan. 28, 2016 WHO warns of Zika's 'explosive spread,' convenes emergency committee
• Jan. 26, 2016 Pharma titans seek out tech partnerships to bring big data to healthcare
• Jan. 26, 2016 Akashi suspends Duchenne trial in another blow to treatment hopes
• Jan. 25, 2016 Bristol-Myers' Opdivo notches two key regulatory victories in US, UK
• Jan. 22, 2016 Powerhouse pharma coalition promises more antibiotics R&D, but calls for better incentives
• Jan. 22, 2016 Reviewing Gilead's formidable 2015: A year marked by higher sales and new criticism
• Jan. 21, 2016 Chinese pharma company slapped with import ban by FDA
• Jan. 20, 2016 WebMD: We're not in negotiations to be bought
• Jan. 20, 2016 Multiple violations cause production halt at Mylan-owned Agila's Polish plant
• Jan. 20, 2016 Amidst falling sales, Medicines Co. reportedly mulling sale
• Jan. 20, 2016 Watchdog report spotlights significant failures in FDA postmarket drug tracking
• Jan. 20, 2016 Gavi commits $5 million in advance for Merck's Ebola vaccine
• Jan. 19, 2016 Biotech Acorda buys Finnish firm Biotie & its Parkinson's candidates for $363M
• Jan. 19, 2016 Novartis' psoriasis mega-blockbuster hopeful Cosentyx nabs 2 new indications
• Jan. 15, 2016 CORRECTED: French drug trial suspended after participant left brain dead, five others critically ill
• Jan. 14, 2016 Pfizer partners with nonprofit Calibr to develop heart failure drugs
• Jan. 14, 2016 Bayer opens OTC drug manufacturing plant in China
• Jan. 14, 2016 WHO declares Liberia free of Ebola, ending West African outbreak
• Jan. 13, 2016 Warning letters reveal some of the FDA's biggest problems with Indian drugmakers
• Jan. 13, 2016 Express Scripts shares slide as Anthem threatens to ditch PBM over drug savings
• Jan. 13, 2016 Pharma battling ballot measures designed to limit drug prices
• Jan. 13, 2016 FDA flags manufacturing deficiencies of Chinese drug supplier
• Jan. 12, 2016 Health committee sends Califf FDA nom to full Senate as Sanders mulls hold
• Jan. 11, 2016 Struggling Mannkind appoints new CEO after withdrawing offer to previous choice
• Jan. 11, 2016 Shire buys Baxalta for $32 billion, ending months-long pursuit
• Jan. 11, 2016 UK investor Woodford reiterates call for Glaxo to be split four ways
• Jan. 7, 2016 Flurry of venture deals hits biopharma ahead of JPMorgan healthcare conference
• Jan. 7, 2016 India's Cadila to snap up plant, animal health products from Pfizer spinoff Zoetis
• Jan. 6, 2016 Biotech startup Vtesse granted FDA breakthrough designation for orphan NPC drug
• Jan. 6, 2016 Gilead grabs priority review for pangenotype hep C combo; Hep B med shown to be safe
• Jan. 6, 2016 MannKind CFO: We're searching for a new Afrezza marketing partner after Sanofi's departure
• Dec. 31, 2015 Shkreli's former company KaloBios files for bankruptcy
• Dec. 28, 2015 Valeant CEO Pearson on medical leave, company being run by 3-man exec group
• Dec. 18, 2015 Bristol-Myers spinning off its entire HIV pipeline to Glaxo for $1.5 billion
• Dec. 17, 2015 Lilly gets its Lantus copycat Basaglar approved by FDA—but not as a biosimilar
• Dec. 11, 2015 Kallyope raises $44M in Series A to launch NYC-based 'gut-brain' biotech
• Dec. 10, 2015 Clinton plan would pump brakes on Pfizer-Allergan deal, other major inversion mergers
• Dec. 9, 2015 Senators mull speedier generics pathway amid outrage over Turing, Valeant price hikes
• Dec. 4, 2015 The 5 pharma vets and 3 newcomers that made BCG's '50 most innovative' firms list
• Nov. 18, 2015 Senators grilled Obama's nominee for FDA chief. Here's how he responded